Paraneoplastic Neurological Syndromes

Autoimmune MONDO:0018215 Pathograph 12 Neurological Disease Autoimmune Disease Cancer-Associated Disease

Paraneoplastic neurological syndromes are rare immune-mediated neurologic disorders triggered by cancer but not caused by direct tumor invasion, metastasis, infection, ischemia, or metabolic disturbance. Tumor expression of antigens shared with the nervous system can elicit high-risk or intermediate-risk neural autoantibodies and T-cell responses that injure the central nervous system, peripheral nervous system, neuromuscular junction, or muscle. Diagnosis integrates the neurologic phenotype, antibody risk category, cancer status, and follow-up using the PNS-Care framework.

Ask OpenScientist

Ask a research question about Paraneoplastic Neurological Syndromes. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
2
Definitions
4
Pathophys.
1
Histopath.
10
Phenotypes
12
Pathograph
4
Genes
7
Treatments
2
Subtypes
50
References
2
Deep Research
🔗

Mappings

MONDO
MONDO:0018215 paraneoplastic neurologic syndrome
skos:exactMatch MONDO
MONDO exact match for the Orphanet/ORDO paraneoplastic neurological syndromes concept ORPHA:36388.
📘

Definitions

2
Remote cancer-associated neurologic syndrome definition
Paraneoplastic neurological syndromes are remote neurologic effects of cancer, distinct from metastasis or other cancer complications.
OTHER
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer that are not caused by the tumor and its metastasis, or by infection, ischemia or metabolic disruptions."
The Orphanet Journal of Rare Diseases review provides the core clinical definition for PNS.
PNS-Care diagnostic evidence levels
Contemporary diagnostic criteria classify PNS evidence as definite, probable, or possible using clinical phenotype, antibody risk category, cancer detection, and follow-up duration.
CASE_DEFINITION
Show evidence (1 reference)
PMID:34006622 SUPPORT Other
"Each level can be reached by using the PNS-Care Score, which combines clinical phenotype, antibody type, the presence or absence of cancer, and time of follow-up."
The 2021 expert consensus defines the PNS-Care score and diagnostic certainty levels.
◆

Subtypes

2
Intracellular Antigen PNS
PNS associated with intracellular neural antigens, including classic onconeural antibody syndromes such as anti-Hu/ANNA-1 and anti-Yo/PCA-1, is generally high cancer-risk and is primarily modeled as T-cell-mediated neural injury with limited immunotherapy responsiveness.
Show evidence (2 references)
PMID:41562781 SUPPORT Other
"distinguish T-cell-mediated syndromes associated with intracellular antigens from antibody-mediated disorders targeting neuronal surface proteins"
This contemporary review supports intracellular-antigen PNS as a distinct immunopathogenic subtype.
PMID:21938556 SUPPORT Other
"Disorders accompanied by autoantibody markers of neural peptide-specific cytotoxic effector T cells"
This review supports cytotoxic T-cell-dominant biology for intracellular/onconeural antibody syndromes.
Surface Antigen PNS
PNS associated with neuronal surface, plasma-membrane, or synaptic antigen targets is modeled as pathogenic autoantibody-mediated synaptic or neuronal signaling dysfunction, often with greater potential reversibility after early immunotherapy.
Show evidence (2 references)
PMID:41562781 SUPPORT Other
"distinguish T-cell-mediated syndromes associated with intracellular antigens from antibody-mediated disorders targeting neuronal surface proteins"
This review explicitly separates antibody-mediated surface-antigen PNS from intracellular-antigen syndromes.
PMID:21938556 SUPPORT Other
"Disorders accompanied by neural plasma membrane-reactive autoantibodies"
This review supports plasma-membrane/synaptic autoantibody disease as a distinct immunopathogenic subtype.
⚙

Pathophysiology

4
Tumor-Neural Antigen Immune Cross-Recognition
A tumor expressing antigens shared with neural tissue can trigger adaptive immunity against tumor cells that cross-recognizes the nervous system.
conventional dendritic cell link cytotoxic T cell link
immune response to tumor cell link ↑ INCREASED antigen processing and presentation of peptide antigen via MHC class I link ↑ INCREASED
nervous system link
Downstream
Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS) Tumor-triggered immunity against intracellular neural antigens can generate cytotoxic T-cell-dominant neural injury.
Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS) Tumor-triggered immunity can also produce surface-antigen autoantibodies that perturb synaptic or neuronal signaling.
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"PNS are caused by autoimmune processes triggered by the cancer and directed against antigens common to both the cancer and the nervous system"
This review directly supports tumor-triggered immune cross-recognition of shared cancer and nervous-system antigens.
Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS)
Intracellular-antigen PNS is dominated by cytotoxic T-cell effector biology against neurons expressing shared tumor-neural antigens. Onconeural antibodies such as anti-Hu or anti-Yo often mark this process, but the destructive injury is modeled through cytotoxic lymphocyte-mediated neuronal death.
cytotoxic T cell link Purkinje cell link
T cell mediated cytotoxicity link ↑ INCREASED apoptotic process link ↑ INCREASED
central nervous system link cerebellum link
Downstream
Multifocal Neurological Dysfunction Cytotoxic neural injury can cause irreversible focal or multifocal neurologic syndromes.
Show evidence (2 references)
PMID:21938556 SUPPORT Other
"Disorders accompanied by autoantibody markers of neural peptide-specific cytotoxic effector T cells"
This review supports cytotoxic T-cell biology in anti-Hu, anti-Yo, and related intracellular-antigen PNS.
PMID:38494293 SUPPORT Human Clinical
"leading to the destruction of Purkinje cells harboring the Yo antigens"
Anti-Yo paraneoplastic cerebellar degeneration provides a concrete example of neuronal destruction in intracellular-antigen PNS.
Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
Surface-antigen PNS involves plasma-membrane or synaptic autoantibodies that can disrupt neuronal communication. These antibody-mediated syndromes are modeled separately from intracellular-antigen disease because the effector mechanism is more directly humoral and often more treatment-responsive.
plasma cell link neuron link
chemical synaptic transmission link ⚠ ABNORMAL B cell mediated immunity link ↑ INCREASED
central nervous system link
Downstream
Multifocal Neurological Dysfunction Surface-antigen autoantibody dysfunction can affect CNS, peripheral nerves, autonomic pathways, and neuromuscular signaling.
Show evidence (2 references)
PMID:21938556 SUPPORT Other
"Disorders accompanied by neural plasma membrane-reactive autoantibodies"
This review supports plasma-membrane-reactive autoantibodies as effectors of synaptic PNS disorders.
PMID:41562781 SUPPORT Other
"antibody-mediated disorders targeting neuronal surface proteins"
This contemporary review supports a distinct surface-antigen antibody-mediated PNS mechanism.
Multifocal Neurological Dysfunction
PNS phenotypes vary by antibody, tumor, and neural target and may include rapidly progressive cerebellar syndrome, encephalitis, opsoclonus-myoclonus, sensory neuropathy, retinopathy, neuromuscular junction dysfunction, or gastrointestinal pseudo-obstruction.
neuron link
brain link cerebellum link hippocampal formation link
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"The most common PNS are Lambert-Eaton myasthenic syndrome (LEMS), subacute cerebellar ataxia, limbic encephalitis (LE), opsoclonus-myoclonus (OM), retinopathies"
This review lists representative neurologic syndromes caused by downstream PNS injury.
✶

Histopathology

1
Yo-Antigen-Expressing Tumors with Immune Infiltration and Purkinje Cell Destruction
Anti-Yo paraneoplastic cerebellar degeneration provides a histopathologic model in which associated breast or gynecologic tumors overexpress Yo antigens, show immune-cell infiltration, and are linked to destruction of Purkinje cells expressing the same antigens.
Show evidence (1 reference)
PMID:38494293 SUPPORT Human Clinical
"The massive infiltration of these tumors by immune cells suggests that they are the site of the immune tolerance breakdown, leading to the destruction of Purkinje cells harboring the Yo antigens."
This review connects tumor immune infiltration, Yo-antigen expression, tolerance breakdown, and Purkinje cell destruction in anti-Yo PNS.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Paraneoplastic Neurological Syndromes Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Digestive 1
Intestinal Pseudo-Obstruction Intestinal pseudo-obstruction (HP:0004389)
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"chronic gastrointestinal pseudoobstruction (CGP)"
Chronic gastrointestinal pseudo-obstruction is included among common PNS phenotypes.
Eye 1
Visual Impairment from Paraneoplastic Retinopathy Visual impairment (HP:0000505)
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"retinopathies (cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR)"
The review lists CAR and MAR retinopathies among PNS phenotypes.
Musculoskeletal 1
Muscle Weakness from Neuromuscular Junction or Muscle Involvement Muscle weakness (HP:0001324)
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"Only the Lambert-Eaton myasthenic syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer."
LEMS is a neuromuscular junction PNS commonly associated with weakness and small-cell lung cancer.
Nervous System 6
Cerebellar Ataxia Ataxia (HP:0001251)
Course: PROGRESSIVE
Show evidence (2 references)
PMID:17480225 SUPPORT Other
"subacute cerebellar ataxia"
Subacute cerebellar ataxia is listed among the most common PNS phenotypes.
DOI:10.3390/biomedicines11051406 SUPPORT Other
"rapidly progressive cerebellar syndrome"
The CNS PNS review identifies rapidly progressive cerebellar syndrome as a high-risk clinical syndrome.
Limbic Encephalitis and Encephalopathy Encephalopathy (HP:0001298)
Temporal: SUBACUTE
Show evidence (2 references)
PMID:17480225 SUPPORT Other
"limbic encephalitis (LE)"
Limbic encephalitis is listed among common PNS phenotypes.
DOI:10.3390/biomedicines11051406 SUPPORT Other
"acute/subacute encephalopathies"
This review highlights acute and subacute encephalopathies as a setting where CNS PNS should be suspected.
Memory Impairment Memory impairment (HP:0002354)
Show evidence (2 references)
PMID:18851928 SUPPORT Human Clinical
"All patients presented with psychiatric symptoms or memory problems"
This anti-NMDAR encephalitis series supports memory problems in a surface-antigen autoimmune encephalitis phenotype that can be paraneoplastic.
PMID:18851928 SUPPORT Human Clinical
"23 presented with short-term memory loss or seizures alone or associated with psychiatric manifestations."
The same series directly supports short-term memory loss among encephalitic surface-antigen presentations.
Atypical Behavior Atypical behavior (HP:0000708)
Show evidence (1 reference)
PMID:18851928 SUPPORT Human Clinical
"77 patients presented with prominent psychiatric symptoms, including anxiety, agitation, bizarre behaviour, delusional or paranoid thoughts, and visual or auditory hallucinations."
This series supports atypical behavioral and psychiatric presentations in anti-NMDAR encephalitis, a tumor-associated surface-antigen autoimmune encephalitis phenotype.
Myoclonus Myoclonus (HP:0001336)
Show evidence (2 references)
PMID:17480225 SUPPORT Other
"opsoclonus-myoclonus (OM)"
Opsoclonus-myoclonus is included among common PNS phenotypes.
PMID:41894019 SUPPORT Human Clinical
"patients (30.6%) developed opsoclonus, and 22.4% developed myoclonus."
This anti-Ri systematic review supports myoclonus as a recurrent paraneoplastic neurologic manifestation.
Sensory Neuropathy Sensory neuropathy (HP:0000763)
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"sensory neuronopathy (SSN)"
Sensory neuronopathy is listed among common PNS phenotypes.
Other 1
Opsoclonus Opsoclonus (HP:0010543)
Show evidence (2 references)
PMID:17480225 SUPPORT Other
"opsoclonus-myoclonus (OM)"
Opsoclonus-myoclonus is included among common PNS phenotypes.
DOI:10.3390/biomedicines11051406 SUPPORT Other
"opsoclonus-myoclonus-ataxia syndrome"
The CNS PNS review identifies opsoclonus-myoclonus-ataxia syndrome among high-risk clinical syndromes.
🧬

Genetic Associations

4
Representative Neural Autoantigen Target Genes (Autoantigen target biomarkers, not monogenic causation)
Show evidence (2 references)
PMID:21938556 SUPPORT Other
"anti-neuronal nuclear antibody type 1 (ANNA-1, aka anti-Hu), Purkinje cell antibody type 1 (PCA-1, aka anti-Yo) and CRMP-5 IgG"
This review supports classic intracellular onconeural autoantigen classes that map to neural antigen target genes.
PMID:21938556 SUPPORT Other
"antibodies targeting voltage-gated potassium channel (VGKC) complex proteins, NMDA and GABA-B receptors"
This review supports neuronal surface or synaptic antigen classes that map to receptor and channel target genes.
CDR2 Yo Autoantigen Tumor Alteration (Somatic tumor autoantigen alteration in anti-Yo paraneoplastic cerebellar degeneration)
Show evidence (1 reference)
PMID:38494293 SUPPORT Human Clinical
"The Yo autoantibodies are directed against the Yo antigens, aberrantly overexpressed by tumor cells with frequent somatic mutations and gene amplifications."
This review supports somatic tumor alteration and overexpression of Yo antigens in anti-Yo PNS.
CDR2L Yo Autoantigen Tumor Alteration (Somatic tumor autoantigen alteration in anti-Yo paraneoplastic cerebellar degeneration)
Show evidence (1 reference)
PMID:38494293 SUPPORT Human Clinical
"The Yo autoantibodies are directed against the Yo antigens, aberrantly overexpressed by tumor cells with frequent somatic mutations and gene amplifications."
This review supports somatic tumor alteration and overexpression of Yo antigens in anti-Yo PNS.
HLA-DQ2 and HLA-DR3 Susceptibility in Hu-PNS (HLA class II susceptibility alleles in Hu-antibody-associated PNS)
Show evidence (2 references)
PMID:20547426 SUPPORT Human Clinical
"The frequency of both HLA-DQ2 and HLA-DR3 was significantly higher in Hu-PNS patients than in HC."
This case-control study supports HLA-DQ2 and HLA-DR3 enrichment in Hu-antibody-associated PNS.
PMID:20547426 SUPPORT Human Clinical
"This study indicates an association between Hu-PNS and presence of HLA-DQ2 and HLA-DR3"
The study conclusion supports HLA-DQ2/HLA-DR3 as susceptibility factors for Hu-PNS.
💊

Treatments

7
Cancer-Directed Therapy
Action: surgical procedure MAXO:0000004
Identifying and treating the underlying tumor is central because tumor removal or control can reduce the antigenic driver of PNS.
Mechanism Target:
INHIBITS Tumor-Neural Antigen Immune Cross-Recognition — Tumor treatment can remove or reduce the source of shared tumor-neural antigens.
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"to date, the best way to stabilize PNS is to treat the cancer as soon as possible."
This review links early cancer treatment with PNS stabilization.
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"to date, the best way to stabilize PNS is to treat the cancer as soon as possible."
The review supports cancer-directed therapy as a core management strategy for PNS.
Immunotherapy
Action: immunotherapy Ontology label: immunotherapy procedure MAXO:0001002
Immunotherapy may be used to suppress the immune process, with treatment choice and prognosis varying by syndrome, antibody target, and tumor control.
Mechanism Target:
MODULATES Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS) — Immunotherapy is intended to suppress pathogenic cytotoxic immune effector responses.
Show evidence (1 reference)
PMID:17480225 SUPPORT Other
"As PNS are believed to be immune-mediated, suppression of the immune response represents another treatment approach."
This review supports immune suppression as a treatment approach for immune-mediated PNS.
MODULATES Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS) — Immunotherapy is intended to modulate pathogenic autoantibody production or activity in surface-antigen PNS.
Show evidence (1 reference)
PMID:21938556 SUPPORT Other
"Disorders accompanied by neural plasma membrane-reactive autoantibodies"
This review supports early immunotherapy responsiveness in neural plasma-membrane/synaptic autoantibody disorders.
Show evidence (2 references)
DOI:10.1177/1756286420985323 SUPPORT Other
"Specific management strategies and prognosis vary widely depending on the underlying etiology."
This management review supports individualized therapy by PNS etiology and syndrome.
PMID:17480225 SUPPORT Other
"suppression of the immune response represents another treatment approach."
The Orphanet Journal of Rare Diseases review supports immunotherapy as a treatment concept.
Corticosteroid Therapy
Action: corticosteroid agent therapy MAXO:0000640
Corticosteroids are used as acute immunosuppressive therapy for autoimmune and paraneoplastic neurologic presentations, particularly when inflammatory CNS or cerebellar involvement is suspected.
Mechanism Target:
MODULATES Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS) — Corticosteroids broadly suppress inflammatory immune effector activity.
Show evidence (1 reference)
PMID:26414229 SUPPORT Human Clinical
"Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
This autoimmune cerebellar ataxia cohort explicitly includes corticosteroids among immunotherapies assessed in paraneoplastic and nonparaneoplastic ataxia subgroups.
MODULATES Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS) — Corticosteroids can reduce inflammatory antibody-associated CNS immune activity.
Show evidence (1 reference)
PMID:26414229 SUPPORT Human Clinical
"Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
This cohort supports corticosteroids as one of the immunotherapy options evaluated for autoimmune neurologic disease.
Show evidence (1 reference)
PMID:26414229 SUPPORT Human Clinical
"Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
The cohort explicitly includes corticosteroids among assessed immunotherapies.
Intravenous Immunoglobulin
Action: intravenous immunoglobulin therapy Ontology label: immunoglobulin infusion therapy MAXO:0001480
Intravenous immunoglobulin is used as antibody-directed or immune-modulating therapy in selected PNS phenotypes, including opsoclonus-myoclonus and autoimmune cerebellar presentations.
Mechanism Target:
MODULATES Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS) — IVIG can modulate pathogenic humoral immune responses and Fc-mediated effector pathways.
Show evidence (1 reference)
PMID:26414229 SUPPORT Human Clinical
"Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
This cohort explicitly includes intravenous immunoglobulin among assessed immunotherapies.
Show evidence (2 references)
PMID:26414229 SUPPORT Human Clinical
"Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
The cohort explicitly includes intravenous immunoglobulin among assessed immunotherapies.
PMID:24342231 SUPPORT Human Clinical
"On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
Opsoclonus-myoclonus biomarker data support IVIG as part of combination immunotherapy.
Plasma Exchange
Action: plasmapheresis Ontology label: Plasmapheresis NCIT:C15304
Plasma exchange is used to reduce circulating pathogenic antibody burden in antibody-mediated PNS or severe autoimmune neurologic presentations.
Mechanism Target:
INHIBITS Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS) — Plasma exchange can remove circulating antibodies and immune mediators.
Show evidence (1 reference)
PMID:26414229 SUPPORT Human Clinical
"Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
This cohort explicitly includes plasma exchange among assessed immunotherapies.
Show evidence (1 reference)
PMID:26414229 SUPPORT Human Clinical
"Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
The cohort explicitly includes plasma exchange among assessed immunotherapies.
Rituximab
Action: Pharmacotherapy NCIT:C15986
Agent: rituximab ↗
Rituximab is an anti-CD20 B-cell-depleting therapy used in selected antibody-mediated or refractory PNS phenotypes, especially when ongoing humoral autoimmunity is suspected.
Mechanism Target:
INHIBITS Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS) — B-cell depletion can reduce renewal of autoreactive B-cell lineages that sustain pathogenic antibody responses.
Show evidence (1 reference)
PMID:24342231 SUPPORT Human Clinical
"On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
Opsoclonus-myoclonus data support rituximab as part of multimodal immunotherapy.
Show evidence (1 reference)
PMID:24342231 SUPPORT Human Clinical
"On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
The study documents rituximab in a combination immunotherapy regimen for opsoclonus-myoclonus syndrome.
Amifampridine for Lambert-Eaton Myasthenic Syndrome
Action: Pharmacotherapy NCIT:C15986
Agent: amifampridine ↗
Amifampridine, also called 3,4-diaminopyridine, is symptomatic therapy for Lambert-Eaton myasthenic syndrome, a neuromuscular-junction PNS phenotype.
Target Phenotypes: Muscle weakness ↗
Show evidence (2 references)
PMID:27997683 SUPPORT Human Clinical
"18 of 48 (38%) patients received 3,4-diaminopyridine (3,4-DAP); 14 of 18 (78%) improved."
This LEMS cohort supports clinical improvement with 3,4-diaminopyridine/amifampridine.
PMID:17480225 SUPPORT Other
"Only the Lambert-Eaton myasthenic syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer."
This PNS review supports LEMS as a paraneoplastic neuromuscular-junction phenotype relevant to symptomatic amifampridine therapy.
🔬

Biochemical Markers

2
High- or Intermediate-Risk Neural Autoantibodies (Positive in subset)
Show evidence (2 references)
PMID:34006622 SUPPORT Other
"The term "onconeural antibody" was replaced by "high risk" (>70% associated with cancer) and "intermediate risk" (30%-70% associated with cancer) antibodies."
The 2021 criteria classify neural antibodies by cancer-association risk.
PMID:17480225 SUPPORT Other
"Unfortunately, about one-third of patients do not have detectable antibodies and 5% to 10% have an atypical antibody that is not well-characterized."
This supports antibody-negative and atypical-antibody PNS subsets.
Cerebrospinal Fluid Neurofilament Light Chain (Elevated in opsoclonus-myoclonus subset)
Show evidence (2 references)
PMID:24342231 SUPPORT Human Clinical
"Only CSF NFL was elevated in untreated OMS versus controls (+83%)."
Pediatric opsoclonus-myoclonus syndrome data support CSF NFL as an axonal-injury biomarker in this PNS-relevant phenotype.
PMID:24342231 SUPPORT Human Clinical
"On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
The same study links multimodal immunotherapy with reduction of CSF NFL.
{ }

Source YAML

click to show 
name: Paraneoplastic Neurological Syndromes
creation_date: "2026-05-16T22:42:45Z"
updated_date: "2026-05-16T23:48:49Z"
category: Autoimmune
parents:
- Neurological Disease
- Autoimmune Disease
- Cancer-Associated Disease
prevalence:
- population: Northeastern Italy population-based cohort, 2009-2017
  percentage: 4.37 per 100,000 prevalence; 0.89 per 100,000 person-years incidence
  evidence:
  - reference: PMID:31552550
    reference_title: "Epidemiology of paraneoplastic neurological syndromes: a population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence of PNS was 0.89/100,000 person-years."
    explanation: The Friuli-Venezia Giulia population-based study provides incidence and prevalence estimates for definite PNS.
  - reference: PMID:31552550
    reference_title: "Epidemiology of paraneoplastic neurological syndromes: a population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The prevalence of PNS was 4.37 per 100,000."
    explanation: The same cohort supports the point-prevalence estimate.
- population: Olmsted County, Minnesota population-based cohort, 1987-2018
  percentage: 5.4 per 100,000 prevalence; 0.6 per 100,000 person-years incidence
  evidence:
  - reference: PMID:34937736
    reference_title: "Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PNS incidence was 0.6/100,000 person-years"
    explanation: The Olmsted County study provides a United States population-based incidence estimate.
  - reference: PMID:34937736
    reference_title: "Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevalence was 5.4/100,000 people."
    explanation: The same study provides a population-based prevalence estimate and documents severe morbidity and mortality.
synonyms:
- PNS
- Paraneoplastic neurologic syndrome
- Paraneoplastic neurologic syndromes
- Nervous system paraneoplastic syndromes
description: >-
  Paraneoplastic neurological syndromes are rare immune-mediated neurologic
  disorders triggered by cancer but not caused by direct tumor invasion,
  metastasis, infection, ischemia, or metabolic disturbance. Tumor expression of
  antigens shared with the nervous system can elicit high-risk or
  intermediate-risk neural autoantibodies and T-cell responses that injure the
  central nervous system, peripheral nervous system, neuromuscular junction, or
  muscle. Diagnosis integrates the neurologic phenotype, antibody risk category,
  cancer status, and follow-up using the PNS-Care framework.
has_subtypes:
- name: Intracellular Antigen PNS
  description: >-
    PNS associated with intracellular neural antigens, including classic
    onconeural antibody syndromes such as anti-Hu/ANNA-1 and anti-Yo/PCA-1, is
    generally high cancer-risk and is primarily modeled as T-cell-mediated neural
    injury with limited immunotherapy responsiveness.
  evidence:
  - reference: PMID:41562781
    reference_title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "distinguish T-cell-mediated syndromes associated with intracellular antigens from antibody-mediated disorders targeting neuronal surface proteins"
    explanation: This contemporary review supports intracellular-antigen PNS as a distinct immunopathogenic subtype.
  - reference: PMID:21938556
    reference_title: 'Paraneoplastic neurological autoimmunity and survival of the neuron: the role of the cancer immunity cycle.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Disorders accompanied by autoantibody markers of neural peptide-specific cytotoxic effector T cells"
    explanation: This review supports cytotoxic T-cell-dominant biology for intracellular/onconeural antibody syndromes.
- name: Surface Antigen PNS
  description: >-
    PNS associated with neuronal surface, plasma-membrane, or synaptic antigen
    targets is modeled as pathogenic autoantibody-mediated synaptic or neuronal
    signaling dysfunction, often with greater potential reversibility after
    early immunotherapy.
  evidence:
  - reference: PMID:41562781
    reference_title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "distinguish T-cell-mediated syndromes associated with intracellular antigens from antibody-mediated disorders targeting neuronal surface proteins"
    explanation: This review explicitly separates antibody-mediated surface-antigen PNS from intracellular-antigen syndromes.
  - reference: PMID:21938556
    reference_title: 'Paraneoplastic neurological autoimmunity and survival of the neuron: the role of the cancer immunity cycle.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Disorders accompanied by neural plasma membrane-reactive autoantibodies"
    explanation: This review supports plasma-membrane/synaptic autoantibody disease as a distinct immunopathogenic subtype.
disease_term:
  preferred_term: paraneoplastic neurologic syndrome
  term:
    id: MONDO:0018215
    label: paraneoplastic neurologic syndrome
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0018215
      label: paraneoplastic neurologic syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO exact match for the Orphanet/ORDO paraneoplastic neurological syndromes concept ORPHA:36388.
definitions:
- name: Remote cancer-associated neurologic syndrome definition
  definition_type: OTHER
  description: >-
    Paraneoplastic neurological syndromes are remote neurologic effects of
    cancer, distinct from metastasis or other cancer complications.
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Paraneoplastic neurological syndromes (PNS) can be defined as remote effects of cancer that are not caused by the tumor and its metastasis, or by infection, ischemia or metabolic disruptions."
    explanation: The Orphanet Journal of Rare Diseases review provides the core clinical definition for PNS.
- name: PNS-Care diagnostic evidence levels
  definition_type: CASE_DEFINITION
  description: >-
    Contemporary diagnostic criteria classify PNS evidence as definite,
    probable, or possible using clinical phenotype, antibody risk category,
    cancer detection, and follow-up duration.
  evidence:
  - reference: PMID:34006622
    reference_title: "Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Each level can be reached by using the PNS-Care Score, which combines clinical phenotype, antibody type, the presence or absence of cancer, and time of follow-up."
    explanation: The 2021 expert consensus defines the PNS-Care score and diagnostic certainty levels.
progression:
- phase: Subacute paraneoplastic neurologic presentation
  age_range: All ages
  notes: >-
    Symptoms often progress over days to months and may precede clinically
    apparent cancer, making neurologic recognition and tumor search central to
    management.
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In most patients, the neurological disorder develops before the cancer becomes clinically overt"
    explanation: This supports the temporal pattern in which neurologic disease can precede cancer detection.
pathophysiology:
- name: Tumor-Neural Antigen Immune Cross-Recognition
  description: >-
    A tumor expressing antigens shared with neural tissue can trigger adaptive
    immunity against tumor cells that cross-recognizes the nervous system.
  biological_processes:
  - preferred_term: immune response to tumor cell
    term:
      id: GO:0002418
      label: immune response to tumor cell
    modifier: INCREASED
  - preferred_term: antigen processing and presentation of peptide antigen via MHC class I
    term:
      id: GO:0002474
      label: antigen processing and presentation of peptide antigen via MHC class I
    modifier: INCREASED
  cell_types:
  - preferred_term: conventional dendritic cell
    term:
      id: CL:0000990
      label: conventional dendritic cell
  - preferred_term: cytotoxic T cell
    term:
      id: CL:0000910
      label: cytotoxic T cell
  locations:
  - preferred_term: nervous system
    term:
      id: UBERON:0001016
      label: nervous system
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "PNS are caused by autoimmune processes triggered by the cancer and directed against antigens common to both the cancer and the nervous system"
    explanation: This review directly supports tumor-triggered immune cross-recognition of shared cancer and nervous-system antigens.
  downstream:
  - target: Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS)
    causal_link_type: DIRECT
    description: Tumor-triggered immunity against intracellular neural antigens can generate cytotoxic T-cell-dominant neural injury.
    evidence:
    - reference: PMID:41562781
      reference_title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "distinguish T-cell-mediated syndromes associated with intracellular antigens from antibody-mediated disorders targeting neuronal surface proteins"
      explanation: This review connects intracellular-antigen PNS to a T-cell-mediated effector branch.
  - target: Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
    causal_link_type: DIRECT
    description: Tumor-triggered immunity can also produce surface-antigen autoantibodies that perturb synaptic or neuronal signaling.
    evidence:
    - reference: PMID:41562781
      reference_title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "distinguish T-cell-mediated syndromes associated with intracellular antigens from antibody-mediated disorders targeting neuronal surface proteins"
      explanation: This review connects surface-antigen PNS to an antibody-mediated effector branch.
- name: Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS)
  description: >-
    Intracellular-antigen PNS is dominated by cytotoxic T-cell effector biology
    against neurons expressing shared tumor-neural antigens. Onconeural
    antibodies such as anti-Hu or anti-Yo often mark this process, but the
    destructive injury is modeled through cytotoxic lymphocyte-mediated neuronal
    death.
  biological_processes:
  - preferred_term: T cell mediated cytotoxicity
    term:
      id: GO:0001913
      label: T cell mediated cytotoxicity
    modifier: INCREASED
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  cell_types:
  - preferred_term: cytotoxic T cell
    term:
      id: CL:0000910
      label: cytotoxic T cell
  - preferred_term: Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  locations:
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  evidence:
  - reference: PMID:21938556
    reference_title: 'Paraneoplastic neurological autoimmunity and survival of the neuron: the role of the cancer immunity cycle.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Disorders accompanied by autoantibody markers of neural peptide-specific cytotoxic effector T cells"
    explanation: This review supports cytotoxic T-cell biology in anti-Hu, anti-Yo, and related intracellular-antigen PNS.
  - reference: PMID:38494293
    reference_title: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "leading to the destruction of Purkinje cells harboring the Yo antigens"
    explanation: Anti-Yo paraneoplastic cerebellar degeneration provides a concrete example of neuronal destruction in intracellular-antigen PNS.
  downstream:
  - target: Multifocal Neurological Dysfunction
    causal_link_type: DIRECT
    description: Cytotoxic neural injury can cause irreversible focal or multifocal neurologic syndromes.
    evidence:
    - reference: PMID:17480225
      reference_title: "Paraneoplastic neurological syndromes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "PNS can affect any part of the central and peripheral nervous system, the neuromuscular junction, and muscle."
      explanation: This review supports the broad anatomic distribution of downstream neurologic dysfunction.
- name: Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
  description: >-
    Surface-antigen PNS involves plasma-membrane or synaptic autoantibodies that
    can disrupt neuronal communication. These antibody-mediated syndromes are
    modeled separately from intracellular-antigen disease because the effector
    mechanism is more directly humoral and often more treatment-responsive.
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
    modifier: ABNORMAL
  - preferred_term: B cell mediated immunity
    term:
      id: GO:0019724
      label: B cell mediated immunity
    modifier: INCREASED
  cell_types:
  - preferred_term: plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  evidence:
  - reference: PMID:21938556
    reference_title: 'Paraneoplastic neurological autoimmunity and survival of the neuron: the role of the cancer immunity cycle.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Disorders accompanied by neural plasma membrane-reactive autoantibodies"
    explanation: This review supports plasma-membrane-reactive autoantibodies as effectors of synaptic PNS disorders.
  - reference: PMID:41562781
    reference_title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "antibody-mediated disorders targeting neuronal surface proteins"
    explanation: This contemporary review supports a distinct surface-antigen antibody-mediated PNS mechanism.
  downstream:
  - target: Multifocal Neurological Dysfunction
    causal_link_type: DIRECT
    description: Surface-antigen autoantibody dysfunction can affect CNS, peripheral nerves, autonomic pathways, and neuromuscular signaling.
    evidence:
    - reference: PMID:17480225
      reference_title: "Paraneoplastic neurological syndromes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "PNS can affect any part of the central and peripheral nervous system, the neuromuscular junction, and muscle."
      explanation: This review supports the broad anatomic distribution of downstream neurologic dysfunction.
- name: Multifocal Neurological Dysfunction
  description: >-
    PNS phenotypes vary by antibody, tumor, and neural target and may include
    rapidly progressive cerebellar syndrome, encephalitis, opsoclonus-myoclonus,
    sensory neuropathy, retinopathy, neuromuscular junction dysfunction, or
    gastrointestinal pseudo-obstruction.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: hippocampal formation
    term:
      id: UBERON:0002421
      label: hippocampal formation
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The most common PNS are Lambert-Eaton myasthenic syndrome (LEMS), subacute cerebellar ataxia, limbic encephalitis (LE), opsoclonus-myoclonus (OM), retinopathies"
    explanation: This review lists representative neurologic syndromes caused by downstream PNS injury.
phenotypes:
- name: Cerebellar Ataxia
  category: Clinical
  description: Rapidly progressive cerebellar dysfunction can cause gait and limb ataxia.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "subacute cerebellar ataxia"
    explanation: Subacute cerebellar ataxia is listed among the most common PNS phenotypes.
  - reference: DOI:10.3390/biomedicines11051406
    reference_title: "Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "rapidly progressive cerebellar syndrome"
    explanation: The CNS PNS review identifies rapidly progressive cerebellar syndrome as a high-risk clinical syndrome.
- name: Limbic Encephalitis and Encephalopathy
  category: Clinical
  description: CNS PNS can present with acute or subacute encephalopathy, memory impairment, seizures, and limbic encephalitis.
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
    temporality: SUBACUTE
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "limbic encephalitis (LE)"
    explanation: Limbic encephalitis is listed among common PNS phenotypes.
  - reference: DOI:10.3390/biomedicines11051406
    reference_title: "Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "acute/subacute encephalopathies"
    explanation: This review highlights acute and subacute encephalopathies as a setting where CNS PNS should be suspected.
- name: Memory Impairment
  category: Clinical
  description: Limbic encephalitis and surface-antigen encephalitis phenotypes can include memory impairment or amnesia.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
  evidence:
  - reference: PMID:18851928
    reference_title: "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients presented with psychiatric symptoms or memory problems"
    explanation: This anti-NMDAR encephalitis series supports memory problems in a surface-antigen autoimmune encephalitis phenotype that can be paraneoplastic.
  - reference: PMID:18851928
    reference_title: "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "23 presented with short-term memory loss or seizures alone or associated with psychiatric manifestations."
    explanation: The same series directly supports short-term memory loss among encephalitic surface-antigen presentations.
- name: Atypical Behavior
  category: Psychiatric
  description: Encephalitic PNS presentations can include psychiatric symptoms or atypical behavior, particularly in anti-NMDAR-type surface-antigen disease.
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:18851928
    reference_title: "Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "77 patients presented with prominent psychiatric symptoms, including anxiety, agitation, bizarre behaviour, delusional or paranoid thoughts, and visual or auditory hallucinations."
    explanation: This series supports atypical behavioral and psychiatric presentations in anti-NMDAR encephalitis, a tumor-associated surface-antigen autoimmune encephalitis phenotype.
- name: Opsoclonus
  category: Clinical
  description: Opsoclonus-myoclonus-ataxia syndrome is a recognized PNS phenotype.
  phenotype_term:
    preferred_term: Opsoclonus
    term:
      id: HP:0010543
      label: Opsoclonus
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "opsoclonus-myoclonus (OM)"
    explanation: Opsoclonus-myoclonus is included among common PNS phenotypes.
  - reference: DOI:10.3390/biomedicines11051406
    reference_title: "Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "opsoclonus-myoclonus-ataxia syndrome"
    explanation: The CNS PNS review identifies opsoclonus-myoclonus-ataxia syndrome among high-risk clinical syndromes.
- name: Myoclonus
  category: Clinical
  description: Myoclonus can occur with paraneoplastic opsoclonus-myoclonus-ataxia and anti-Ri PNS presentations.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "opsoclonus-myoclonus (OM)"
    explanation: Opsoclonus-myoclonus is included among common PNS phenotypes.
  - reference: PMID:41894019
    reference_title: 'Clinical features of paraneoplastic neurologic syndromes with anti-Ri antibodies: PRISMA systematic review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients (30.6%) developed opsoclonus, and 22.4% developed myoclonus."
    explanation: This anti-Ri systematic review supports myoclonus as a recurrent paraneoplastic neurologic manifestation.
- name: Sensory Neuropathy
  category: Clinical
  description: Paraneoplastic sensory neuronopathy or neuropathy can present with sensory loss and ataxic gait.
  phenotype_term:
    preferred_term: Sensory neuropathy
    term:
      id: HP:0000763
      label: Sensory neuropathy
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "sensory neuronopathy (SSN)"
    explanation: Sensory neuronopathy is listed among common PNS phenotypes.
- name: Intestinal Pseudo-Obstruction
  category: Clinical
  description: Autonomic or enteric nervous-system involvement can cause chronic gastrointestinal pseudo-obstruction.
  phenotype_term:
    preferred_term: Intestinal pseudo-obstruction
    term:
      id: HP:0004389
      label: Intestinal pseudo-obstruction
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "chronic gastrointestinal pseudoobstruction (CGP)"
    explanation: Chronic gastrointestinal pseudo-obstruction is included among common PNS phenotypes.
- name: Visual Impairment from Paraneoplastic Retinopathy
  category: Clinical
  description: Cancer-associated and melanoma-associated retinopathies can cause visual symptoms.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "retinopathies (cancer-associated retinopathy (CAR) and melanoma-associated retinopathy (MAR)"
    explanation: The review lists CAR and MAR retinopathies among PNS phenotypes.
- name: Muscle Weakness from Neuromuscular Junction or Muscle Involvement
  category: Clinical
  description: LEMS, dermatomyositis, and other neuromuscular PNS phenotypes can manifest with weakness.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Only the Lambert-Eaton myasthenic syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer."
    explanation: LEMS is a neuromuscular junction PNS commonly associated with weakness and small-cell lung cancer.
histopathology:
- name: Yo-Antigen-Expressing Tumors with Immune Infiltration and Purkinje Cell Destruction
  description: >-
    Anti-Yo paraneoplastic cerebellar degeneration provides a histopathologic
    model in which associated breast or gynecologic tumors overexpress Yo
    antigens, show immune-cell infiltration, and are linked to destruction of
    Purkinje cells expressing the same antigens.
  context: Anti-Yo/PCA-1 paraneoplastic cerebellar degeneration
  evidence:
  - reference: PMID:38494293
    reference_title: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The massive infiltration of these tumors by immune cells suggests that they are the site of the immune tolerance breakdown, leading to the destruction of Purkinje cells harboring the Yo antigens."
    explanation: This review connects tumor immune infiltration, Yo-antigen expression, tolerance breakdown, and Purkinje cell destruction in anti-Yo PNS.
biochemical:
- name: High- or Intermediate-Risk Neural Autoantibodies
  presence: Positive in subset
  notes: >-
    Antibody testing supports diagnosis and tumor search, but absence of
    detectable antibodies does not exclude PNS.
  evidence:
  - reference: PMID:34006622
    reference_title: "Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The term \"onconeural antibody\" was replaced by \"high risk\" (>70% associated with cancer) and \"intermediate risk\" (30%-70% associated with cancer) antibodies."
    explanation: The 2021 criteria classify neural antibodies by cancer-association risk.
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Unfortunately, about one-third of patients do not have detectable antibodies and 5% to 10% have an atypical antibody that is not well-characterized."
    explanation: This supports antibody-negative and atypical-antibody PNS subsets.
- name: Cerebrospinal Fluid Neurofilament Light Chain
  presence: Elevated in opsoclonus-myoclonus subset
  notes: >-
    CSF neurofilament light chain is an axonal-injury biomarker that can be
    elevated in untreated opsoclonus-myoclonus syndrome and may decline after
    multimodal immunotherapy.
  evidence:
  - reference: PMID:24342231
    reference_title: CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Only CSF NFL was elevated in untreated OMS versus controls (+83%)."
    explanation: Pediatric opsoclonus-myoclonus syndrome data support CSF NFL as an axonal-injury biomarker in this PNS-relevant phenotype.
  - reference: PMID:24342231
    reference_title: CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
    explanation: The same study links multimodal immunotherapy with reduction of CSF NFL.
genetic:
- name: Representative Neural Autoantigen Target Genes
  presence: Autoantigen targets in antibody-defined subsets
  association: Autoantigen target biomarkers, not monogenic causation
  relationship_type: BIOMARKER
  notes: >-
    PNS is not a single-gene disorder. Antibody-defined subsets map to neural
    autoantigen targets such as ELAVL4/HuD (HGNC:3315), CDR2 (HGNC:1799),
    CDR2L (HGNC:29999), NOVA1 (HGNC:7886), NOVA2 (HGNC:7887), KLHL11
    (HGNC:19008), GRIN1 (HGNC:4584), LGI1 (HGNC:6572), and CACNA1A
    (HGNC:1388).
  evidence:
  - reference: PMID:21938556
    reference_title: 'Paraneoplastic neurological autoimmunity and survival of the neuron: the role of the cancer immunity cycle.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "anti-neuronal nuclear antibody type 1 (ANNA-1, aka anti-Hu), Purkinje cell antibody type 1 (PCA-1, aka anti-Yo) and CRMP-5 IgG"
    explanation: This review supports classic intracellular onconeural autoantigen classes that map to neural antigen target genes.
  - reference: PMID:21938556
    reference_title: 'Paraneoplastic neurological autoimmunity and survival of the neuron: the role of the cancer immunity cycle.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "antibodies targeting voltage-gated potassium channel (VGKC) complex proteins, NMDA and GABA-B receptors"
    explanation: This review supports neuronal surface or synaptic antigen classes that map to receptor and channel target genes.
- name: CDR2 Yo Autoantigen Tumor Alteration
  gene_term:
    preferred_term: CDR2
    term:
      id: hgnc:1799
      label: CDR2
  association: Somatic tumor autoantigen alteration in anti-Yo paraneoplastic cerebellar degeneration
  relationship_type: BIOMARKER
  variant_origin: SOMATIC
  notes: >-
    CDR2 is one of the curated Yo/PCA-1 antigen target genes; tumor
    overexpression and somatic alteration of Yo antigens can participate in
    tolerance breakdown.
  evidence:
  - reference: PMID:38494293
    reference_title: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Yo autoantibodies are directed against the Yo antigens, aberrantly overexpressed by tumor cells with frequent somatic mutations and gene amplifications."
    explanation: This review supports somatic tumor alteration and overexpression of Yo antigens in anti-Yo PNS.
- name: CDR2L Yo Autoantigen Tumor Alteration
  gene_term:
    preferred_term: CDR2L
    term:
      id: hgnc:29999
      label: CDR2L
  association: Somatic tumor autoantigen alteration in anti-Yo paraneoplastic cerebellar degeneration
  relationship_type: BIOMARKER
  variant_origin: SOMATIC
  notes: >-
    CDR2L is curated alongside CDR2 as a Yo/PCA-1 antigen target gene; this entry
    distinguishes antigen-target biology from inherited monogenic causation.
  evidence:
  - reference: PMID:38494293
    reference_title: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Yo autoantibodies are directed against the Yo antigens, aberrantly overexpressed by tumor cells with frequent somatic mutations and gene amplifications."
    explanation: This review supports somatic tumor alteration and overexpression of Yo antigens in anti-Yo PNS.
- name: HLA-DQ2 and HLA-DR3 Susceptibility in Hu-PNS
  presence: Enriched in Hu-antibody-associated subset
  association: HLA class II susceptibility alleles in Hu-antibody-associated PNS
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >-
    HLA-DQ2 and HLA-DR3 are susceptibility haplotypes for the Hu-antibody PNS
    subset rather than necessary or sufficient causes of PNS.
  evidence:
  - reference: PMID:20547426
    reference_title: HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The frequency of both HLA-DQ2 and HLA-DR3 was significantly higher in Hu-PNS patients than in HC."
    explanation: This case-control study supports HLA-DQ2 and HLA-DR3 enrichment in Hu-antibody-associated PNS.
  - reference: PMID:20547426
    reference_title: HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study indicates an association between Hu-PNS and presence of HLA-DQ2 and HLA-DR3"
    explanation: The study conclusion supports HLA-DQ2/HLA-DR3 as susceptibility factors for Hu-PNS.
treatments:
- name: Cancer-Directed Therapy
  description: >-
    Identifying and treating the underlying tumor is central because tumor
    removal or control can reduce the antigenic driver of PNS.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_mechanisms:
  - target: Tumor-Neural Antigen Immune Cross-Recognition
    treatment_effect: INHIBITS
    description: Tumor treatment can remove or reduce the source of shared tumor-neural antigens.
    evidence:
    - reference: PMID:17480225
      reference_title: "Paraneoplastic neurological syndromes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "to date, the best way to stabilize PNS is to treat the cancer as soon as possible."
      explanation: This review links early cancer treatment with PNS stabilization.
  evidence:
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "to date, the best way to stabilize PNS is to treat the cancer as soon as possible."
    explanation: The review supports cancer-directed therapy as a core management strategy for PNS.
- name: Immunotherapy
  description: >-
    Immunotherapy may be used to suppress the immune process, with treatment
    choice and prognosis varying by syndrome, antibody target, and tumor
    control.
  treatment_term:
    preferred_term: immunotherapy
    term:
      id: MAXO:0001002
      label: immunotherapy procedure
  target_mechanisms:
  - target: Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS)
    treatment_effect: MODULATES
    description: Immunotherapy is intended to suppress pathogenic cytotoxic immune effector responses.
    evidence:
    - reference: PMID:17480225
      reference_title: "Paraneoplastic neurological syndromes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "As PNS are believed to be immune-mediated, suppression of the immune response represents another treatment approach."
      explanation: This review supports immune suppression as a treatment approach for immune-mediated PNS.
  - target: Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
    treatment_effect: MODULATES
    description: Immunotherapy is intended to modulate pathogenic autoantibody production or activity in surface-antigen PNS.
    evidence:
    - reference: PMID:21938556
      reference_title: 'Paraneoplastic neurological autoimmunity and survival of the neuron: the role of the cancer immunity cycle.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Disorders accompanied by neural plasma membrane-reactive autoantibodies"
      explanation: This review supports early immunotherapy responsiveness in neural plasma-membrane/synaptic autoantibody disorders.
  evidence:
  - reference: DOI:10.1177/1756286420985323
    reference_title: "Paraneoplastic neurological syndromes: clinical presentations and management"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Specific management strategies and prognosis vary widely depending on the underlying etiology."
    explanation: This management review supports individualized therapy by PNS etiology and syndrome.
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "suppression of the immune response represents another treatment approach."
    explanation: The Orphanet Journal of Rare Diseases review supports immunotherapy as a treatment concept.
- name: Corticosteroid Therapy
  description: >-
    Corticosteroids are used as acute immunosuppressive therapy for autoimmune
    and paraneoplastic neurologic presentations, particularly when inflammatory
    CNS or cerebellar involvement is suspected.
  treatment_term:
    preferred_term: corticosteroid agent therapy
    term:
      id: MAXO:0000640
      label: corticosteroid agent therapy
  target_mechanisms:
  - target: Cytotoxic T Cell-Mediated Neuronal Destruction (Intracellular Antigen PNS)
    treatment_effect: MODULATES
    description: Corticosteroids broadly suppress inflammatory immune effector activity.
    evidence:
    - reference: PMID:26414229
      reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
      explanation: This autoimmune cerebellar ataxia cohort explicitly includes corticosteroids among immunotherapies assessed in paraneoplastic and nonparaneoplastic ataxia subgroups.
  - target: Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
    treatment_effect: MODULATES
    description: Corticosteroids can reduce inflammatory antibody-associated CNS immune activity.
    evidence:
    - reference: PMID:26414229
      reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
      explanation: This cohort supports corticosteroids as one of the immunotherapy options evaluated for autoimmune neurologic disease.
  evidence:
  - reference: PMID:26414229
    reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
    explanation: The cohort explicitly includes corticosteroids among assessed immunotherapies.
- name: Intravenous Immunoglobulin
  description: >-
    Intravenous immunoglobulin is used as antibody-directed or immune-modulating
    therapy in selected PNS phenotypes, including opsoclonus-myoclonus and
    autoimmune cerebellar presentations.
  treatment_term:
    preferred_term: intravenous immunoglobulin therapy
    term:
      id: MAXO:0001480
      label: immunoglobulin infusion therapy
  target_mechanisms:
  - target: Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
    treatment_effect: MODULATES
    description: IVIG can modulate pathogenic humoral immune responses and Fc-mediated effector pathways.
    evidence:
    - reference: PMID:26414229
      reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
      explanation: This cohort explicitly includes intravenous immunoglobulin among assessed immunotherapies.
  evidence:
  - reference: PMID:26414229
    reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
    explanation: The cohort explicitly includes intravenous immunoglobulin among assessed immunotherapies.
  - reference: PMID:24342231
    reference_title: CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
    explanation: Opsoclonus-myoclonus biomarker data support IVIG as part of combination immunotherapy.
- name: Plasma Exchange
  description: >-
    Plasma exchange is used to reduce circulating pathogenic antibody burden in
    antibody-mediated PNS or severe autoimmune neurologic presentations.
  treatment_term:
    preferred_term: plasmapheresis
    term:
      id: NCIT:C15304
      label: Plasmapheresis
  target_mechanisms:
  - target: Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
    treatment_effect: INHIBITS
    description: Plasma exchange can remove circulating antibodies and immune mediators.
    evidence:
    - reference: PMID:26414229
      reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
      explanation: This cohort explicitly includes plasma exchange among assessed immunotherapies.
  evidence:
  - reference: PMID:26414229
    reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Responses to immunotherapy (corticosteroids, intravenous immunoglobulin, plasma exchange, and immunosuppressants)"
    explanation: The cohort explicitly includes plasma exchange among assessed immunotherapies.
- name: Rituximab
  description: >-
    Rituximab is an anti-CD20 B-cell-depleting therapy used in selected
    antibody-mediated or refractory PNS phenotypes, especially when ongoing
    humoral autoimmunity is suspected.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  target_mechanisms:
  - target: Pathogenic Autoantibody-Mediated Synaptic Dysfunction (Surface Antigen PNS)
    treatment_effect: INHIBITS
    description: B-cell depletion can reduce renewal of autoreactive B-cell lineages that sustain pathogenic antibody responses.
    evidence:
    - reference: PMID:24342231
      reference_title: CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
      explanation: Opsoclonus-myoclonus data support rituximab as part of multimodal immunotherapy.
  evidence:
  - reference: PMID:24342231
    reference_title: CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "On combination treatment with front-loaded ACTH, IVIg, rituximab, median CSF NFL decreased by 60% to control levels."
    explanation: The study documents rituximab in a combination immunotherapy regimen for opsoclonus-myoclonus syndrome.
- name: Amifampridine for Lambert-Eaton Myasthenic Syndrome
  description: >-
    Amifampridine, also called 3,4-diaminopyridine, is symptomatic therapy for
    Lambert-Eaton myasthenic syndrome, a neuromuscular-junction PNS phenotype.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amifampridine
      term:
        id: CHEBI:135948
        label: amifampridine
  target_phenotypes:
  - preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:27997683
    reference_title: 'Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "18 of 48 (38%) patients received 3,4-diaminopyridine (3,4-DAP); 14 of 18 (78%) improved."
    explanation: This LEMS cohort supports clinical improvement with 3,4-diaminopyridine/amifampridine.
  - reference: PMID:17480225
    reference_title: "Paraneoplastic neurological syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Only the Lambert-Eaton myasthenic syndrome is relatively frequent, occurring in about 1% of patients with small cell lung cancer."
    explanation: This PNS review supports LEMS as a paraneoplastic neuromuscular-junction phenotype relevant to symptomatic amifampridine therapy.
datasets: []
references:
- reference: DOI:10.1177/1756286420985323
  title: 'Paraneoplastic neurological syndromes: clinical presentations and management'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
- reference: DOI:10.1212/nxi.0000000000001014
  title: Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
- reference: DOI:10.3390/biomedicines11051406
  title: 'Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
- reference: PMID:34006622
  title: Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
- reference: PMID:41562781
  title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
- reference: DOI:10.1007/s00415-019-09544-1
  title: 'Epidemiology of paraneoplastic neurological syndromes: a population-based study'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  findings:
  - statement: A Northeastern Italy population-based study estimated definite PNS incidence near 1 per 100,000 person-years.
    supporting_text: The incidence of PNS was 0.89/100,000 person-years.
    evidence:
    - reference: PMID:31552550
      reference_title: "Epidemiology of paraneoplastic neurological syndromes: a population-based study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The incidence of PNS was 0.89/100,000 person-years."
      explanation: Deep research cited this population-based study as relevant epidemiologic literature for Paraneoplastic Neurological Syndromes.
- reference: DOI:10.1080/14737175.2021.1927713
  title: Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  findings:
  - statement: PNS pathogenesis involves cross-reactive immunity against antigens shared by tumor and nervous-system tissue.
    supporting_text: These syndromes are the result of a cross-reactive immune response against antigens shared by the tumor and the nervous system.
    evidence:
    - reference: PMID:33960258
      reference_title: "Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "These syndromes are the result of a cross-reactive immune response against antigens shared by the tumor and the nervous system."
      explanation: Deep research cited this review as supporting the tumor-neural immune cross-recognition mechanism.
- reference: DOI:10.1136/jitc-2023-008724
  title: Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  findings:
  - statement: Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns.
    supporting_text: Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns.
    evidence:
    - reference: DOI:10.1136/jitc-2023-008724
      reference_title: Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: DOI:10.1136/practneurol-2021-003073
  title: 'Paraneoplastic neurological syndromes: a practical approach to diagnosis and management'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  findings:
  - statement: Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour.
    supporting_text: Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour.
    evidence:
    - reference: DOI:10.1136/practneurol-2021-003073
      reference_title: 'Paraneoplastic neurological syndromes: a practical approach to diagnosis and management'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: DOI:10.1212/nxi.0000000000001124
  title: Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  findings:
  - statement: A United States population-based study found PNS to be rare but associated with severe morbidity and mortality.
    supporting_text: PNSs are rare neurologic disorders but are associated with severe morbidity and mortality.
    evidence:
    - reference: PMID:34937736
      reference_title: "Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "PNSs are rare neurologic disorders but are associated with severe morbidity and mortality."
      explanation: Deep research cited this study for population burden and morbidity.
- reference: DOI:10.1212/nxi.0000000000200318
  title: Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  findings:
  - statement: Nationwide antibody-testing data show high analytic performance but only modest positive predictive values for some rare AIE/PNS tests.
    supporting_text: Sensitivity and specificity were high (>95%) to very high (>99%) for most tests in both serum and CSF.
    evidence:
    - reference: PMID:39467237
      reference_title: "Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes: A Nationwide Study on Epidemiology and Antibody Testing Performance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Sensitivity and specificity were high (>95%) to very high (>99%) for most tests in both serum and CSF."
      explanation: Deep research cited this nationwide study for antibody testing performance and interpretation pitfalls in AIE/PNS.
- reference: DOI:10.3390/antib12030050
  title: Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  findings:
  - statement: Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells.
    supporting_text: Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells.
    evidence:
    - reference: DOI:10.3390/antib12030050
      reference_title: Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: DOI:10.3390/antib15010008
  title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-falcon.md
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability.
    supporting_text: Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability.
    evidence:
    - reference: DOI:10.3390/antib15010008
      reference_title: 'Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:16635427
  title: Paraneoplastic neurologic syndromes.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2006 May;6(3):193-9. doi: 10.1007/s11910-006-0005-z.'
    supporting_text: '2006 May;6(3):193-9. doi: 10.1007/s11910-006-0005-z.'
    evidence:
    - reference: PMID:16635427
      reference_title: Paraneoplastic neurologic syndromes.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2006 May;6(3):193-9. doi: 10.1007/s11910-006-0005-z.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:20547426
  title: HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Hypothetically, T cells are involved in the pathogenesis of paraneoplastic neurological syndromes associated with Hu-antibodies (Hu-PNS).
    supporting_text: Hypothetically, T cells are involved in the pathogenesis of paraneoplastic neurological syndromes associated with Hu-antibodies (Hu-PNS).
    evidence:
    - reference: PMID:20547426
      reference_title: HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Hypothetically, T cells are involved in the pathogenesis of paraneoplastic neurological syndromes associated with Hu-antibodies (Hu-PNS).
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:21938556
  title: 'Paraneoplastic encephalomyelopathies: pathology and mechanisms.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2011 Oct;122(4):381-400. doi: 10.1007/s00401-011-0876-1.'
    supporting_text: '2011 Oct;122(4):381-400. doi: 10.1007/s00401-011-0876-1.'
    evidence:
    - reference: PMID:21938556
      reference_title: 'Paraneoplastic encephalomyelopathies: pathology and mechanisms.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2011 Oct;122(4):381-400. doi: 10.1007/s00401-011-0876-1.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:24342231
  title: CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2014 Jan 15;266(1-2):75-81. doi: 10.1016/j.jneuroim.2013.11.004.'
    supporting_text: '2014 Jan 15;266(1-2):75-81. doi: 10.1016/j.jneuroim.2013.11.004.'
    evidence:
    - reference: PMID:24342231
      reference_title: CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2014 Jan 15;266(1-2):75-81. doi: 10.1016/j.jneuroim.2013.11.004.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:26414229
  title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2015 Nov;72(11):1304-12. doi: 10.1001/jamaneurol.2015.2378.'
    supporting_text: '2015 Nov;72(11):1304-12. doi: 10.1001/jamaneurol.2015.2378.'
    evidence:
    - reference: PMID:26414229
      reference_title: Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2015 Nov;72(11):1304-12. doi: 10.1001/jamaneurol.2015.2378.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:27997683
  title: 'Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2017 Sep;56(3):421-426. doi: 10.1002/mus.25520.'
    supporting_text: '2017 Sep;56(3):421-426. doi: 10.1002/mus.25520.'
    evidence:
    - reference: PMID:27997683
      reference_title: 'Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2017 Sep;56(3):421-426. doi: 10.1002/mus.25520.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:29178913
  title: 'Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Cancer is a significant complication contributing to increased mortality in idiopathic inflammatory myopathies (IIMs), and the association between IIMs and cancer has been extensively reported.
    supporting_text: Cancer is a significant complication contributing to increased mortality in idiopathic inflammatory myopathies (IIMs), and the association between IIMs and cancer has been extensively reported.
    evidence:
    - reference: PMID:29178913
      reference_title: 'Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Cancer is a significant complication contributing to increased mortality in idiopathic inflammatory myopathies (IIMs), and the association between IIMs and cancer has been extensively reported.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:29355452
  title: Retrospective study of paraneoplastic neurological syndromes in a Chinese Han population from Shandong, East China.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2018 Sep;128(9):821-827. doi: 10.1080/00207454.2018.1430693.'
    supporting_text: '2018 Sep;128(9):821-827. doi: 10.1080/00207454.2018.1430693.'
    evidence:
    - reference: PMID:29355452
      reference_title: Retrospective study of paraneoplastic neurological syndromes in a Chinese Han population from Shandong, East China.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2018 Sep;128(9):821-827. doi: 10.1080/00207454.2018.1430693.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:31831596
  title: Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747.'
    supporting_text: '2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747.'
    evidence:
    - reference: PMID:31831596
      reference_title: Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:31953318
  title: Clinical significance of Kelch-like protein 11 antibodies.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2020 Jan 17;7(3):e666. doi: 10.1212/NXI.0000000000000666.'
    supporting_text: '2020 Jan 17;7(3):e666. doi: 10.1212/NXI.0000000000000666.'
    evidence:
    - reference: PMID:31953318
      reference_title: Clinical significance of Kelch-like protein 11 antibodies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2020 Jan 17;7(3):e666. doi: 10.1212/NXI.0000000000000666.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:34903638
  title: Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2021 Dec 13;9(1):e1122. doi: 10.1212/NXI.0000000000001122.'
    supporting_text: '2021 Dec 13;9(1):e1122. doi: 10.1212/NXI.0000000000001122.'
    evidence:
    - reference: PMID:34903638
      reference_title: Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: '2021 Dec 13;9(1):e1122. doi: 10.1212/NXI.0000000000001122.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:36110924
  title: Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: There was no nationwide epidemiological study of Lambert-Eaton myasthenic syndrome (LEMS) in Japan; therefore, we conducted a nationwide survey.
    supporting_text: There was no nationwide epidemiological study of Lambert-Eaton myasthenic syndrome (LEMS) in Japan; therefore, we conducted a nationwide survey.
    evidence:
    - reference: PMID:36110924
      reference_title: Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: There was no nationwide epidemiological study of Lambert-Eaton myasthenic syndrome (LEMS) in Japan; therefore, we conducted a nationwide survey.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:36896371
  title: Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2023 Feb;14(2):71-75. doi: 10.14740/jmc4043.'
    supporting_text: '2023 Feb;14(2):71-75. doi: 10.14740/jmc4043.'
    evidence:
    - reference: PMID:36896371
      reference_title: Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2023 Feb;14(2):71-75. doi: 10.14740/jmc4043.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:37507235
  title: Cancer detection after a 9-year course of Lambert-Eaton myasthenic syndrome complicated by anti-Hu associated limbic encephalitis.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2023 Sep;33(9):90-92. doi: 10.1016/j.nmd.2023.06.011.'
    supporting_text: '2023 Sep;33(9):90-92. doi: 10.1016/j.nmd.2023.06.011.'
    evidence:
    - reference: PMID:37507235
      reference_title: Cancer detection after a 9-year course of Lambert-Eaton myasthenic syndrome complicated by anti-Hu associated limbic encephalitis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2023 Sep;33(9):90-92. doi: 10.1016/j.nmd.2023.06.011.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:37680668
  title: 'Spontaneous regression of small cell lung cancer associated with Lambert-Eaton Myasthenic Syndrome: Case report.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2023 Sep 2;18(11):4036-4041. doi: 10.1016/j.radcr.2023.08.059. eCollection 2023 Nov.'
    supporting_text: '2023 Sep 2;18(11):4036-4041. doi: 10.1016/j.radcr.2023.08.059. eCollection 2023 Nov.'
    evidence:
    - reference: PMID:37680668
      reference_title: 'Spontaneous regression of small cell lung cancer associated with Lambert-Eaton Myasthenic Syndrome: Case report.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2023 Sep 2;18(11):4036-4041. doi: 10.1016/j.radcr.2023.08.059. eCollection 2023 Nov.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:38183975
  title: Updates in the Management of Paraneoplastic Syndrome.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2024 Feb;44(1):36-46. doi: 10.1055/s-0043-1777353.'
    supporting_text: '2024 Feb;44(1):36-46. doi: 10.1055/s-0043-1777353.'
    evidence:
    - reference: PMID:38183975
      reference_title: Updates in the Management of Paraneoplastic Syndrome.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Feb;44(1):36-46. doi: 10.1055/s-0043-1777353.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:38494293
  title: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2024;200:409-417. doi: 10.1016/B978-0-12-823912-4.00014-1.'
    supporting_text: '2024;200:409-417. doi: 10.1016/B978-0-12-823912-4.00014-1.'
    evidence:
    - reference: PMID:38494293
      reference_title: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2024;200:409-417. doi: 10.1016/B978-0-12-823912-4.00014-1.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:39050850
  title: HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2024 Jul 10;15:1423149. doi: 10.3389/fimmu.2024.1423149. eCollection 2024.'
    supporting_text: '2024 Jul 10;15:1423149. doi: 10.3389/fimmu.2024.1423149. eCollection 2024.'
    evidence:
    - reference: PMID:39050850
      reference_title: HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Jul 10;15:1423149. doi: 10.3389/fimmu.2024.1423149. eCollection 2024.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:39307617
  title: 'Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2024 Nov;180(9):982-988. doi: 10.1016/j.neurol.2024.08.007.'
    supporting_text: '2024 Nov;180(9):982-988. doi: 10.1016/j.neurol.2024.08.007.'
    evidence:
    - reference: PMID:39307617
      reference_title: 'Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2024 Nov;180(9):982-988. doi: 10.1016/j.neurol.2024.08.007.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:39321395
  title: Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2024 Dec;11(6):e200316. doi: 10.1212/NXI.0000000000200316.'
    supporting_text: '2024 Dec;11(6):e200316. doi: 10.1212/NXI.0000000000200316.'
    evidence:
    - reference: PMID:39321395
      reference_title: Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2024 Dec;11(6):e200316. doi: 10.1212/NXI.0000000000200316.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:39859226
  title: IgG-NR2B-A Potentially Valuable Biomarker in the Management of Refractory Anti-NMDAR Encephalitis.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2025 Jan 9;26(2):513. doi: 10.3390/ijms26020513.'
    supporting_text: '2025 Jan 9;26(2):513. doi: 10.3390/ijms26020513.'
    evidence:
    - reference: PMID:39859226
      reference_title: IgG-NR2B-A Potentially Valuable Biomarker in the Management of Refractory Anti-NMDAR Encephalitis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Jan 9;26(2):513. doi: 10.3390/ijms26020513.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:40034005
  title: 'Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Epidemiological frequency measures serve as reference point for patients, clinicians, researchers, and policymakers.
    supporting_text: Epidemiological frequency measures serve as reference point for patients, clinicians, researchers, and policymakers.
    evidence:
    - reference: PMID:40034005
      reference_title: 'Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Epidemiological frequency measures serve as reference point for patients, clinicians, researchers, and policymakers.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:40042691
  title: 'Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7.'
    supporting_text: '2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7.'
    evidence:
    - reference: PMID:40042691
      reference_title: 'Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:40780589
  title: 'Clinical phenotype and outcomes in autoimmune encephalitis after herpes simplex virus encephalitis: A systematic review and meta-analysis.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Autoimmune encephalitis after herpes simplex virus encephalitis (HSVE-AE) represents the intersection of central nervous system infection and autoimmunity.
    supporting_text: Autoimmune encephalitis after herpes simplex virus encephalitis (HSVE-AE) represents the intersection of central nervous system infection and autoimmunity.
    evidence:
    - reference: PMID:40780589
      reference_title: 'Clinical phenotype and outcomes in autoimmune encephalitis after herpes simplex virus encephalitis: A systematic review and meta-analysis.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Autoimmune encephalitis after herpes simplex virus encephalitis (HSVE-AE) represents the intersection of central nervous system infection and autoimmunity.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41290487
  title: Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar;85(3):519-533. doi: 10.1016/j.ard.2025.10.018.'
    supporting_text: '2026 Mar;85(3):519-533. doi: 10.1016/j.ard.2025.10.018.'
    evidence:
    - reference: PMID:41290487
      reference_title: Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Mar;85(3):519-533. doi: 10.1016/j.ard.2025.10.018.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41291493
  title: 'Lambert-Eaton myasthenic syndrome presenting with occult mediastinal small cell carcinoma and positivity for anti-CV2/CRMP5 and anti-SOX1 antibodies: a case report.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by proximal muscle weakness, autonomic dysfunction and hyporeflexia.
    supporting_text: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by proximal muscle weakness, autonomic dysfunction and hyporeflexia.
    evidence:
    - reference: PMID:41291493
      reference_title: 'Lambert-Eaton myasthenic syndrome presenting with occult mediastinal small cell carcinoma and positivity for anti-CV2/CRMP5 and anti-SOX1 antibodies: a case report.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by proximal muscle weakness, autonomic dysfunction and hyporeflexia.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41488641
  title: Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: The suppressive effects of immune checkpoint inhibitors (ICIs) on anti-tumor immunity have been well documented.
    supporting_text: The suppressive effects of immune checkpoint inhibitors (ICIs) on anti-tumor immunity have been well documented.
    evidence:
    - reference: PMID:41488641
      reference_title: Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The suppressive effects of immune checkpoint inhibitors (ICIs) on anti-tumor immunity have been well documented.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41488792
  title: 'Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment.
    supporting_text: Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment.
    evidence:
    - reference: PMID:41488792
      reference_title: 'Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41499721
  title: 'Relative Frequency and Distinctive Features of Anti-Ma2 Nonparaneoplastic Neurologic Disorders: A French Cohort Study.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar;13(2):e200538. doi: 10.1212/NXI.0000000000200538.'
    supporting_text: '2026 Mar;13(2):e200538. doi: 10.1212/NXI.0000000000200538.'
    evidence:
    - reference: PMID:41499721
      reference_title: 'Relative Frequency and Distinctive Features of Anti-Ma2 Nonparaneoplastic Neurologic Disorders: A French Cohort Study.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Mar;13(2):e200538. doi: 10.1212/NXI.0000000000200538.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41573575
  title: 'Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Jan 7;16:1715164. doi: 10.3389/fimmu.2025.1715164. eCollection 2025.'
    supporting_text: '2026 Jan 7;16:1715164. doi: 10.3389/fimmu.2025.1715164. eCollection 2025.'
    evidence:
    - reference: PMID:41573575
      reference_title: 'Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Jan 7;16:1715164. doi: 10.3389/fimmu.2025.1715164. eCollection 2025.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41633558
  title: Two Cases of vNOTES Assisted Vaginal Adnexectomy in Management of Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis Secondary to Ovarian Teratoma.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Jan-Dec;19(1):e70254. doi: 10.1111/ases.70254.'
    supporting_text: '2026 Jan-Dec;19(1):e70254. doi: 10.1111/ases.70254.'
    evidence:
    - reference: PMID:41633558
      reference_title: Two Cases of vNOTES Assisted Vaginal Adnexectomy in Management of Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis Secondary to Ovarian Teratoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: '2026 Jan-Dec;19(1):e70254. doi: 10.1111/ases.70254.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41694384
  title: 'Case Report: Anti-neural cell adhesion molecule 1 antibody-positive encephalitis presenting with schizophrenia-like symptoms and an ovarian teratoma.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Jan 30;17:1587199. doi: 10.3389/fimmu.2026.1587199. eCollection 2026.'
    supporting_text: '2026 Jan 30;17:1587199. doi: 10.3389/fimmu.2026.1587199. eCollection 2026.'
    evidence:
    - reference: PMID:41694384
      reference_title: 'Case Report: Anti-neural cell adhesion molecule 1 antibody-positive encephalitis presenting with schizophrenia-like symptoms and an ovarian teratoma.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Jan 30;17:1587199. doi: 10.3389/fimmu.2026.1587199. eCollection 2026.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41811514
  title: 'Alternative diagnoses of suspected paraneoplastic neurological syndromes: a population-based study.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar 11;273(3):200. doi: 10.1007/s00415-026-13737-w.'
    supporting_text: '2026 Mar 11;273(3):200. doi: 10.1007/s00415-026-13737-w.'
    evidence:
    - reference: PMID:41811514
      reference_title: 'Alternative diagnoses of suspected paraneoplastic neurological syndromes: a population-based study.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Mar 11;273(3):200. doi: 10.1007/s00415-026-13737-w.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41871563
  title: 'Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children.
    supporting_text: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children.
    evidence:
    - reference: PMID:41871563
      reference_title: 'Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41894019
  title: 'Clinical features of paraneoplastic neurologic syndromes with anti-Ri antibodies: PRISMA systematic review.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar 27;273(4):235. doi: 10.1007/s00415-026-13762-9.'
    supporting_text: '2026 Mar 27;273(4):235. doi: 10.1007/s00415-026-13762-9.'
    evidence:
    - reference: PMID:41894019
      reference_title: 'Clinical features of paraneoplastic neurologic syndromes with anti-Ri antibodies: PRISMA systematic review.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Mar 27;273(4):235. doi: 10.1007/s00415-026-13762-9.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41917496
  title: Anti-NMDAR encephalitis impairs intrinsic hippocampal dynamics through neuronal hypercoupling, hub dominance, and aberrant ensembles.
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: '2026 Mar 31. doi: 10.1038/s41380-026-03568-6.'
    supporting_text: '2026 Mar 31. doi: 10.1038/s41380-026-03568-6.'
    evidence:
    - reference: PMID:41917496
      reference_title: Anti-NMDAR encephalitis impairs intrinsic hippocampal dynamics through neuronal hypercoupling, hub dominance, and aberrant ensembles.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: '2026 Mar 31. doi: 10.1038/s41380-026-03568-6.'
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
- reference: PMID:41972167
  title: 'Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database.'
  found_in:
  - Paraneoplastic_Neurological_Syndromes-deep-research-openscientist.md
  findings:
  - statement: Immune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment.
    supporting_text: Immune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment.
    evidence:
    - reference: PMID:41972167
      reference_title: 'Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database.'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Immune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment.
      explanation: Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
📚

References & Deep Research

References

50
DOI:10.1177/1756286420985323
Paraneoplastic neurological syndromes: clinical presentations and management
No top-level findings curated for this source.
DOI:10.1212/nxi.0000000000001014
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
No top-level findings curated for this source.
DOI:10.3390/biomedicines11051406
Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment
No top-level findings curated for this source.
PMID:34006622
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
No top-level findings curated for this source.
PMID:41562781
Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management.
No top-level findings curated for this source.
DOI:10.1007/s00415-019-09544-1
Epidemiology of paraneoplastic neurological syndromes: a population-based study
1 finding
A Northeastern Italy population-based study estimated definite PNS incidence near 1 per 100,000 person-years.
"The incidence of PNS was 0.89/100,000 person-years."
Show evidence (1 reference)
PMID:31552550 SUPPORT Human Clinical
"The incidence of PNS was 0.89/100,000 person-years."
Deep research cited this population-based study as relevant epidemiologic literature for Paraneoplastic Neurological Syndromes.
DOI:10.1080/14737175.2021.1927713
Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes
1 finding
PNS pathogenesis involves cross-reactive immunity against antigens shared by tumor and nervous-system tissue.
"These syndromes are the result of a cross-reactive immune response against antigens shared by the tumor and the nervous system."
Show evidence (1 reference)
PMID:33960258 SUPPORT Human Clinical
"These syndromes are the result of a cross-reactive immune response against antigens shared by the tumor and the nervous system."
Deep research cited this review as supporting the tumor-neural immune cross-recognition mechanism.
DOI:10.1136/jitc-2023-008724
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
1 finding
Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns.
"Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns."
Show evidence (1 reference)
DOI:10.1136/jitc-2023-008724 SUPPORT Human Clinical
"Patients with paraneoplastic syndromes (PNS) are excluded from clinical trials involving immune checkpoint inhibitors (ICIs) due to safety concerns."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
DOI:10.1136/practneurol-2021-003073
Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
1 finding
Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour.
"Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour."
Show evidence (1 reference)
DOI:10.1136/practneurol-2021-003073 SUPPORT Human Clinical
"Paraneoplastic neurological syndromes (PNS) are the immune-mediated effects of a remote cancer and are characterised by an autoantibody response against antigens expressed by the tumour."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
DOI:10.1212/nxi.0000000000001124
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes
1 finding
A United States population-based study found PNS to be rare but associated with severe morbidity and mortality.
"PNSs are rare neurologic disorders but are associated with severe morbidity and mortality."
Show evidence (1 reference)
PMID:34937736 SUPPORT Human Clinical
"PNSs are rare neurologic disorders but are associated with severe morbidity and mortality."
Deep research cited this study for population burden and morbidity.
DOI:10.1212/nxi.0000000000200318
Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes
1 finding
Nationwide antibody-testing data show high analytic performance but only modest positive predictive values for some rare AIE/PNS tests.
"Sensitivity and specificity were high (>95%) to very high (>99%) for most tests in both serum and CSF."
Show evidence (1 reference)
PMID:39467237 SUPPORT Human Clinical
"Sensitivity and specificity were high (>95%) to very high (>99%) for most tests in both serum and CSF."
Deep research cited this nationwide study for antibody testing performance and interpretation pitfalls in AIE/PNS.
DOI:10.3390/antib12030050
Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes
1 finding
Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells.
"Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells."
Show evidence (1 reference)
DOI:10.3390/antib12030050 SUPPORT Other
"Paraneoplastic antibody syndromes result from the anti-tumor antibody response against normal antigens ectopically expressed by tumor cells."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
DOI:10.3390/antib15010008
Paraneoplastic Neurological Syndromes: Advances and Future Perspectives in Immunopathogenesis and Management
1 finding
Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability.
"Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability."
Show evidence (1 reference)
DOI:10.3390/antib15010008 SUPPORT Human Clinical
"Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:16635427
Paraneoplastic neurologic syndromes.
1 finding
2006 May;6(3):193-9. doi: 10.1007/s11910-006-0005-z.
"2006 May;6(3):193-9. doi: 10.1007/s11910-006-0005-z."
Show evidence (1 reference)
PMID:16635427 SUPPORT Human Clinical
"2006 May;6(3):193-9. doi: 10.1007/s11910-006-0005-z."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:20547426
HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.
1 finding
Hypothetically, T cells are involved in the pathogenesis of paraneoplastic neurological syndromes associated with Hu-antibodies (Hu-PNS).
"Hypothetically, T cells are involved in the pathogenesis of paraneoplastic neurological syndromes associated with Hu-antibodies (Hu-PNS)."
Show evidence (1 reference)
PMID:20547426 SUPPORT Human Clinical
"Hypothetically, T cells are involved in the pathogenesis of paraneoplastic neurological syndromes associated with Hu-antibodies (Hu-PNS)."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:21938556
Paraneoplastic encephalomyelopathies: pathology and mechanisms.
1 finding
2011 Oct;122(4):381-400. doi: 10.1007/s00401-011-0876-1.
"2011 Oct;122(4):381-400. doi: 10.1007/s00401-011-0876-1."
Show evidence (1 reference)
PMID:21938556 SUPPORT Other
"2011 Oct;122(4):381-400. doi: 10.1007/s00401-011-0876-1."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:24342231
CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
1 finding
2014 Jan 15;266(1-2):75-81. doi: 10.1016/j.jneuroim.2013.11.004.
"2014 Jan 15;266(1-2):75-81. doi: 10.1016/j.jneuroim.2013.11.004."
Show evidence (1 reference)
PMID:24342231 SUPPORT Human Clinical
"2014 Jan 15;266(1-2):75-81. doi: 10.1016/j.jneuroim.2013.11.004."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:26414229
Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.
1 finding
2015 Nov;72(11):1304-12. doi: 10.1001/jamaneurol.2015.2378.
"2015 Nov;72(11):1304-12. doi: 10.1001/jamaneurol.2015.2378."
Show evidence (1 reference)
PMID:26414229 SUPPORT Human Clinical
"2015 Nov;72(11):1304-12. doi: 10.1001/jamaneurol.2015.2378."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:27997683
Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.
1 finding
2017 Sep;56(3):421-426. doi: 10.1002/mus.25520.
"2017 Sep;56(3):421-426. doi: 10.1002/mus.25520."
Show evidence (1 reference)
PMID:27997683 SUPPORT Human Clinical
"2017 Sep;56(3):421-426. doi: 10.1002/mus.25520."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:29178913
Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study.
1 finding
Cancer is a significant complication contributing to increased mortality in idiopathic inflammatory myopathies (IIMs), and the association between IIMs and cancer has been extensively reported.
"Cancer is a significant complication contributing to increased mortality in idiopathic inflammatory myopathies (IIMs), and the association between IIMs and cancer has been extensively reported."
Show evidence (1 reference)
PMID:29178913 SUPPORT Other
"Cancer is a significant complication contributing to increased mortality in idiopathic inflammatory myopathies (IIMs), and the association between IIMs and cancer has been extensively reported."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:29355452
Retrospective study of paraneoplastic neurological syndromes in a Chinese Han population from Shandong, East China.
1 finding
2018 Sep;128(9):821-827. doi: 10.1080/00207454.2018.1430693.
"2018 Sep;128(9):821-827. doi: 10.1080/00207454.2018.1430693."
Show evidence (1 reference)
PMID:29355452 SUPPORT Human Clinical
"2018 Sep;128(9):821-827. doi: 10.1080/00207454.2018.1430693."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:31831596
Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome.
1 finding
2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747.
"2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747."
Show evidence (1 reference)
PMID:31831596 SUPPORT Human Clinical
"2020 Feb 4;94(5):e511-e520. doi: 10.1212/WNL.0000000000008747."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:31953318
Clinical significance of Kelch-like protein 11 antibodies.
1 finding
2020 Jan 17;7(3):e666. doi: 10.1212/NXI.0000000000000666.
"2020 Jan 17;7(3):e666. doi: 10.1212/NXI.0000000000000666."
Show evidence (1 reference)
PMID:31953318 SUPPORT Human Clinical
"2020 Jan 17;7(3):e666. doi: 10.1212/NXI.0000000000000666."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:34903638
Allosteric Modulation of NMDARs Reverses Patients' Autoantibody Effects in Mice.
1 finding
2021 Dec 13;9(1):e1122. doi: 10.1212/NXI.0000000000001122.
"2021 Dec 13;9(1):e1122. doi: 10.1212/NXI.0000000000001122."
Show evidence (1 reference)
PMID:34903638 SUPPORT Model Organism
"2021 Dec 13;9(1):e1122. doi: 10.1212/NXI.0000000000001122."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:36110924
Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan.
1 finding
There was no nationwide epidemiological study of Lambert-Eaton myasthenic syndrome (LEMS) in Japan; therefore, we conducted a nationwide survey.
"There was no nationwide epidemiological study of Lambert-Eaton myasthenic syndrome (LEMS) in Japan; therefore, we conducted a nationwide survey."
Show evidence (1 reference)
PMID:36110924 SUPPORT Other
"There was no nationwide epidemiological study of Lambert-Eaton myasthenic syndrome (LEMS) in Japan; therefore, we conducted a nationwide survey."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:36896371
Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome.
1 finding
2023 Feb;14(2):71-75. doi: 10.14740/jmc4043.
"2023 Feb;14(2):71-75. doi: 10.14740/jmc4043."
Show evidence (1 reference)
PMID:36896371 SUPPORT Other
"2023 Feb;14(2):71-75. doi: 10.14740/jmc4043."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:37507235
Cancer detection after a 9-year course of Lambert-Eaton myasthenic syndrome complicated by anti-Hu associated limbic encephalitis.
1 finding
2023 Sep;33(9):90-92. doi: 10.1016/j.nmd.2023.06.011.
"2023 Sep;33(9):90-92. doi: 10.1016/j.nmd.2023.06.011."
Show evidence (1 reference)
PMID:37507235 SUPPORT Other
"2023 Sep;33(9):90-92. doi: 10.1016/j.nmd.2023.06.011."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:37680668
Spontaneous regression of small cell lung cancer associated with Lambert-Eaton Myasthenic Syndrome: Case report.
1 finding
2023 Sep 2;18(11):4036-4041. doi: 10.1016/j.radcr.2023.08.059. eCollection 2023 Nov.
"2023 Sep 2;18(11):4036-4041. doi: 10.1016/j.radcr.2023.08.059. eCollection 2023 Nov."
Show evidence (1 reference)
PMID:37680668 SUPPORT Human Clinical
"2023 Sep 2;18(11):4036-4041. doi: 10.1016/j.radcr.2023.08.059. eCollection 2023 Nov."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:38183975
Updates in the Management of Paraneoplastic Syndrome.
1 finding
2024 Feb;44(1):36-46. doi: 10.1055/s-0043-1777353.
"2024 Feb;44(1):36-46. doi: 10.1055/s-0043-1777353."
Show evidence (1 reference)
PMID:38183975 SUPPORT Other
"2024 Feb;44(1):36-46. doi: 10.1055/s-0043-1777353."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:38494293
Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies.
1 finding
2024;200:409-417. doi: 10.1016/B978-0-12-823912-4.00014-1.
"2024;200:409-417. doi: 10.1016/B978-0-12-823912-4.00014-1."
Show evidence (1 reference)
PMID:38494293 SUPPORT Human Clinical
"2024;200:409-417. doi: 10.1016/B978-0-12-823912-4.00014-1."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:39050850
HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis.
1 finding
2024 Jul 10;15:1423149. doi: 10.3389/fimmu.2024.1423149. eCollection 2024.
"2024 Jul 10;15:1423149. doi: 10.3389/fimmu.2024.1423149. eCollection 2024."
Show evidence (1 reference)
PMID:39050850 SUPPORT Other
"2024 Jul 10;15:1423149. doi: 10.3389/fimmu.2024.1423149. eCollection 2024."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:39307617
Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: A mini-review.
1 finding
2024 Nov;180(9):982-988. doi: 10.1016/j.neurol.2024.08.007.
"2024 Nov;180(9):982-988. doi: 10.1016/j.neurol.2024.08.007."
Show evidence (1 reference)
PMID:39307617 SUPPORT Human Clinical
"2024 Nov;180(9):982-988. doi: 10.1016/j.neurol.2024.08.007."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:39321395
Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice.
1 finding
2024 Dec;11(6):e200316. doi: 10.1212/NXI.0000000000200316.
"2024 Dec;11(6):e200316. doi: 10.1212/NXI.0000000000200316."
Show evidence (1 reference)
PMID:39321395 SUPPORT Other
"2024 Dec;11(6):e200316. doi: 10.1212/NXI.0000000000200316."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:39859226
IgG-NR2B-A Potentially Valuable Biomarker in the Management of Refractory Anti-NMDAR Encephalitis.
1 finding
2025 Jan 9;26(2):513. doi: 10.3390/ijms26020513.
"2025 Jan 9;26(2):513. doi: 10.3390/ijms26020513."
Show evidence (1 reference)
PMID:39859226 SUPPORT Other
"2025 Jan 9;26(2):513. doi: 10.3390/ijms26020513."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:40034005
Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature.
1 finding
Epidemiological frequency measures serve as reference point for patients, clinicians, researchers, and policymakers.
"Epidemiological frequency measures serve as reference point for patients, clinicians, researchers, and policymakers."
Show evidence (1 reference)
PMID:40034005 SUPPORT Other
"Epidemiological frequency measures serve as reference point for patients, clinicians, researchers, and policymakers."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:40042691
Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review.
1 finding
2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7.
"2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7."
Show evidence (1 reference)
PMID:40042691 SUPPORT Other
"2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:40780589
Clinical phenotype and outcomes in autoimmune encephalitis after herpes simplex virus encephalitis: A systematic review and meta-analysis.
1 finding
Autoimmune encephalitis after herpes simplex virus encephalitis (HSVE-AE) represents the intersection of central nervous system infection and autoimmunity.
"Autoimmune encephalitis after herpes simplex virus encephalitis (HSVE-AE) represents the intersection of central nervous system infection and autoimmunity."
Show evidence (1 reference)
PMID:40780589 SUPPORT Other
"Autoimmune encephalitis after herpes simplex virus encephalitis (HSVE-AE) represents the intersection of central nervous system infection and autoimmunity."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41290487
Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis.
1 finding
2026 Mar;85(3):519-533. doi: 10.1016/j.ard.2025.10.018.
"2026 Mar;85(3):519-533. doi: 10.1016/j.ard.2025.10.018."
Show evidence (1 reference)
PMID:41290487 SUPPORT Other
"2026 Mar;85(3):519-533. doi: 10.1016/j.ard.2025.10.018."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41291493
Lambert-Eaton myasthenic syndrome presenting with occult mediastinal small cell carcinoma and positivity for anti-CV2/CRMP5 and anti-SOX1 antibodies: a case report.
1 finding
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by proximal muscle weakness, autonomic dysfunction and hyporeflexia.
"Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by proximal muscle weakness, autonomic dysfunction and hyporeflexia."
Show evidence (1 reference)
PMID:41291493 SUPPORT Other
"Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by proximal muscle weakness, autonomic dysfunction and hyporeflexia."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41488641
Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors.
1 finding
The suppressive effects of immune checkpoint inhibitors (ICIs) on anti-tumor immunity have been well documented.
"The suppressive effects of immune checkpoint inhibitors (ICIs) on anti-tumor immunity have been well documented."
Show evidence (1 reference)
PMID:41488641 SUPPORT Other
"The suppressive effects of immune checkpoint inhibitors (ICIs) on anti-tumor immunity have been well documented."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41488792
Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.
1 finding
Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment.
"Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment."
Show evidence (1 reference)
PMID:41488792 SUPPORT Other
"Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41499721
Relative Frequency and Distinctive Features of Anti-Ma2 Nonparaneoplastic Neurologic Disorders: A French Cohort Study.
1 finding
2026 Mar;13(2):e200538. doi: 10.1212/NXI.0000000000200538.
"2026 Mar;13(2):e200538. doi: 10.1212/NXI.0000000000200538."
Show evidence (1 reference)
PMID:41499721 SUPPORT Other
"2026 Mar;13(2):e200538. doi: 10.1212/NXI.0000000000200538."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41573575
Clinical characteristics and prognosis of paraneoplastic syndromes: a single-center cohort study in Northern China.
1 finding
2026 Jan 7;16:1715164. doi: 10.3389/fimmu.2025.1715164. eCollection 2025.
"2026 Jan 7;16:1715164. doi: 10.3389/fimmu.2025.1715164. eCollection 2025."
Show evidence (1 reference)
PMID:41573575 SUPPORT Other
"2026 Jan 7;16:1715164. doi: 10.3389/fimmu.2025.1715164. eCollection 2025."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41633558
Two Cases of vNOTES Assisted Vaginal Adnexectomy in Management of Paraneoplastic Anti-N-Methyl-D-Aspartate Receptor Encephalitis Secondary to Ovarian Teratoma.
1 finding
2026 Jan-Dec;19(1):e70254. doi: 10.1111/ases.70254.
"2026 Jan-Dec;19(1):e70254. doi: 10.1111/ases.70254."
Show evidence (1 reference)
PMID:41633558 SUPPORT Human Clinical
"2026 Jan-Dec;19(1):e70254. doi: 10.1111/ases.70254."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41694384
Case Report: Anti-neural cell adhesion molecule 1 antibody-positive encephalitis presenting with schizophrenia-like symptoms and an ovarian teratoma.
1 finding
2026 Jan 30;17:1587199. doi: 10.3389/fimmu.2026.1587199. eCollection 2026.
"2026 Jan 30;17:1587199. doi: 10.3389/fimmu.2026.1587199. eCollection 2026."
Show evidence (1 reference)
PMID:41694384 SUPPORT Other
"2026 Jan 30;17:1587199. doi: 10.3389/fimmu.2026.1587199. eCollection 2026."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41811514
Alternative diagnoses of suspected paraneoplastic neurological syndromes: a population-based study.
1 finding
2026 Mar 11;273(3):200. doi: 10.1007/s00415-026-13737-w.
"2026 Mar 11;273(3):200. doi: 10.1007/s00415-026-13737-w."
Show evidence (1 reference)
PMID:41811514 SUPPORT Other
"2026 Mar 11;273(3):200. doi: 10.1007/s00415-026-13737-w."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41871563
Neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome: an important yet overlooked diagnosis in pediatric ataxia.
1 finding
Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children.
"Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children."
Show evidence (1 reference)
PMID:41871563 SUPPORT Human Clinical
"Opsoclonus-myoclonus-ataxia syndrome (OMAS) is a rare, immune-mediated neurological disorder, often associated with neuroblastoma (NB) in children."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41894019
Clinical features of paraneoplastic neurologic syndromes with anti-Ri antibodies: PRISMA systematic review.
1 finding
2026 Mar 27;273(4):235. doi: 10.1007/s00415-026-13762-9.
"2026 Mar 27;273(4):235. doi: 10.1007/s00415-026-13762-9."
Show evidence (1 reference)
PMID:41894019 SUPPORT Other
"2026 Mar 27;273(4):235. doi: 10.1007/s00415-026-13762-9."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41917496
Anti-NMDAR encephalitis impairs intrinsic hippocampal dynamics through neuronal hypercoupling, hub dominance, and aberrant ensembles.
1 finding
2026 Mar 31. doi: 10.1038/s41380-026-03568-6.
"2026 Mar 31. doi: 10.1038/s41380-026-03568-6."
Show evidence (1 reference)
PMID:41917496 SUPPORT Other
"2026 Mar 31. doi: 10.1038/s41380-026-03568-6."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.
PMID:41972167
Neurotoxicity of immune checkpoint inhibitors: a retrospective pharmacovigilance study using FAERS database.
1 finding
Immune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment.
"Immune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment."
Show evidence (1 reference)
PMID:41972167 SUPPORT Other
"Immune checkpoint inhibitors (ICIs), an antitumor therapeutic strategy, have shown great potential for cancer treatment."
Deep research cited this publication as relevant literature for Paraneoplastic Neurological Syndromes.

Deep Research

2
Falcon ▸
Paraneoplastic Neurological Syndromes (PNS): Comprehensive Disease Characteristics Report
Edison Scientific Literature 32 citations 2026-05-16T16:08:55.373207

Paraneoplastic Neurological Syndromes (PNS): Comprehensive Disease Characteristics Report

1. Disease Information

Overview / definition

Paraneoplastic neurologic(al) syndromes (PNS) are immune-mediated neurologic disorders caused by a remote effect of cancer (i.e., not explained by direct tumor invasion/metastasis, infection, metabolic derangements, or anticancer treatment toxicity) and reflect an antitumor immune response that cross-reacts with neural antigens (graus2021updateddiagnosticcriteria pages 1-2, binks2022paraneoplasticneurologicalsyndromes pages 1-1, vogrig2020epidemiologyofparaneoplastic pages 1-2). The 2021 international consensus update emphasizes the clinical–immunologic–oncologic heterogeneity of PNS and formalizes risk-stratified phenotypes and antibodies for diagnosis (graus2021updateddiagnosticcriteria pages 1-2).

Common synonyms / alternative names

  • Paraneoplastic neurologic disorders / paraneoplastic neurological disorders (binks2022paraneoplasticneurologicalsyndromes pages 1-1)
  • Paraneoplastic antibody syndromes (in contexts emphasizing antibody biomarkers) (boldicke2023diagnosisandtreatment pages 4-5)

Key identifiers (ontology/coding)

Using the provided toolchain (paper-centric retrieval), explicit MONDO, Orphanet (ORPHA), MeSH descriptor IDs, and specific ICD-10/ICD-11 codes for “paraneoplastic neurological syndromes” were not successfully retrieved from authoritative ontology/coding resources in the current evidence set. Therefore, these identifiers cannot be asserted here without risking fabrication.

Evidence source type note: The present report is derived from aggregated disease-level resources (consensus criteria, population-based cohorts, nationwide testing-performance studies, and real-world observational cohorts), not from individual EHR case records, unless explicitly noted as case series/cohort studies.

Recommended curation action for the knowledge base: supplement this entry with direct pulls from MONDO/Orphanet/MeSH/ICD browsers (outside the current paper-only tool context) to populate stable ontology identifiers.

2. Etiology

Primary causal factors (mechanistic)

PNS are triggered by malignancies that express neuronal (or glial) antigens, generating immune responses that then damage the nervous system. The immune response can be antibody-mediated (particularly for neuronal surface targets) or predominantly T-cell mediated (particularly for intracellular/onconeural antigen targets) (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).

Risk factors

Cancer types commonly associated: Reviews and population-based data consistently highlight (small-cell) lung cancer, gynecologic tumors (including breast/ovarian associations in some antibody-defined syndromes), thymoma, lymphoma, and neuroblastoma in children as recurring cancer associations (blaes2021pathogenesisdiagnosisand pages 1-3, vogrig2020epidemiologyofparaneoplastic pages 1-2).

Immune checkpoint inhibitor (ICI) exposure as a risk context: The 2021 criteria explicitly provide recommendations for syndromes triggered by ICIs (graus2021updateddiagnosticcriteria pages 1-2). Real-world oncology cohorts show that PNS exacerbations and de novo PNS can occur early during ICI therapy and may lead to ICI interruption and immunosuppressive treatment (nassar2024clinicaloutcomesand pages 3-5, nassar2024clinicaloutcomesand pages 1-2).

Protective factors

No protective genetic variants or environmental protective factors were identified in the current evidence set.

Gene–environment interactions

No established gene–environment interaction evidence was identified in the current evidence set.

3. Phenotypes

Current clinical phenotype framework (2021 PNS-Care)

The updated criteria replace older “classical” terminology with high-risk phenotypes and introduce intermediate-risk phenotypes; antibodies are similarly stratified into high-risk (>70% cancer association), intermediate-risk (30–70%), and lower-risk (<30%) categories (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6).

Common phenotypes and relative frequencies (population-based)

In a population-based incidence study in Northeastern Italy (2009–2017), the most common definite PNS were limbic encephalitis (31%), cerebellar degeneration (28%), and encephalomyelitis (20%) (vogrig2020epidemiologyofparaneoplastic pages 1-2).

Phenotype characteristics (general)

PNS frequently present with acute/subacute or rapidly progressive neurologic syndromes; in many patients the neurologic syndrome precedes tumor diagnosis, supporting the need for repeated malignancy surveillance when initial screening is negative (blaes2021pathogenesisdiagnosisand pages 1-3).

Quality-of-life / disability impact

PNS are associated with substantial morbidity and mortality at the population level (shah2022populationbasedepidemiologystudy pages 1-3). In a U.S. population-based study (Olmsted County, 1987–2018), total disability-adjusted life years (DALYs) for 28 PNS patients were 472.7 years, indicating large burden from years of life lost plus disability (shah2022populationbasedepidemiologystudy pages 1-3).

Suggested HPO terms (examples; to be curated per patient phenotype)

Because PNS are syndromically diverse, HPO mapping is typically phenotype-specific. Example mappings: - Limbic encephalitis: Seizures (HP:0001250), Memory impairment (HP:0002354), Altered mental status/encephalopathy (e.g., HP:0012638) - Rapidly progressive cerebellar syndrome: Cerebellar ataxia (HP:0001251), Dysarthria (HP:0001260), Nystagmus (HP:0000639) - Sensory neuronopathy: Sensory neuropathy (HP:0000763), Areflexia (HP:0001284)

(These are ontology suggestions; specific term selection should be confirmed against HPO definitions and clinical context.)

4. Genetic / Molecular Information

“Causal genes” and pathogenic variants

PNS are not typically monogenic disorders; no germline causal genes/variants were supported by the current evidence set.

Molecular targets (antigens) implicated by autoantibodies

Instead of inherited gene causality, PNS are commonly defined by immune responses to neural antigens (intracellular or neuronal surface targets). The 2021 criteria and recent reviews list antibody targets including intracellular antigens (e.g., Hu/ANNA1, Yo/PCA1, CV2/CRMP5, Ri/ANNA2, Ma2/Ta, amphiphysin, KLHL11) and surface/extracellular antigens (e.g., NMDAR, LGI1, Caspr2, GABAB receptor, AMPAR, Tr/DNER) (kerstens2024autoimmuneencephalitisand pages 1-2, graus2021updateddiagnosticcriteria pages 4-6).

Suggested gene/protein identifiers (for knowledge base linkage)

Where antibody targets correspond to proteins, they can be linked to HGNC/UniProt entries during curation (e.g., PNMA2 for Ma2/Ta; KLHL11; DNER; AMPH). (Note: this is a linkage suggestion; the current evidence set supports the antibody/antigen names but not specific HGNC IDs.)

5. Environmental Information

No non-cancer environmental toxin/radiation/pollution exposures were supported as causal contributors in the current evidence set.

6. Mechanism / Pathophysiology

Core mechanistic dichotomy

Two broad immunopathogenic categories are emphasized: 1) Intracellular/onconeural antigen–associated PNS: antibodies serve mainly as biomarkers; neuronal injury is thought to be largely T-cell mediated (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1). 2) Neuronal surface/extracellular antigen–associated PNS: antibodies can be directly pathogenic and these syndromes are often more immunotherapy responsive (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).

Causal chain (typical)

Tumor expresses neural antigen → immune priming (humoral and/or cellular) → cross-reactive immune attack on nervous system targets → inflammatory CSF/MRI changes may develop → clinical syndrome consistent with targeted neuroanatomy/receptor physiology (e.g., limbic circuits; cerebellar Purkinje pathways; synaptic receptors) (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, vogrig2020epidemiologyofparaneoplastic pages 1-2).

Immune system involvement (cell types)

  • Cytotoxic T-lymphocyte–associated injury is strongly implicated for intracellular/onconeural antigen syndromes (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).
  • Antibody-mediated synaptic dysfunction is emphasized for neuronal surface receptor/channel antibodies (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).

Suggested GO biological process terms (examples)

  • Adaptive immune response (GO:0002250)
  • T cell mediated cytotoxicity (GO:0001913)
  • Complement activation (GO:0006956) (more relevant to antibody effector mechanisms; confirm per syndrome)

Suggested Cell Ontology (CL) terms (examples)

  • CD8-positive, alpha-beta T cell (CL:0000625)
  • B cell (CL:0000236)
  • Plasma cell (CL:0000786)

(These are ontology suggestions; they should be refined based on syndrome/antibody class.)

7. Anatomical Structures Affected

Organ/system level

Primary involvement is the nervous system (central and/or peripheral). Clinical syndromes include limbic encephalitis, rapidly progressive cerebellar syndrome, encephalomyelitis, sensory neuronopathy, and neuromuscular junction disorders such as LEMS (vogrig2020epidemiologyofparaneoplastic pages 1-2, graus2021updateddiagnosticcriteria pages 4-6).

Suggested UBERON terms (examples)

  • Brain (UBERON:0000955)
  • Cerebellum (UBERON:0002037)
  • Spinal cord (UBERON:0002240)
  • Peripheral nerve (UBERON:0001021)

8. Temporal Development

Onset patterns

The panel proposes that intermediate-risk phenotypes are particularly suggestive when onset is rapidly progressive (<3 months) or accompanied by inflammatory findings in CSF/MRI (graus2021updateddiagnosticcriteria pages 4-6).

Tumor–neurologic timing

PNS can precede tumor diagnosis, motivating structured repeat tumor surveillance strategies when initial screening is negative (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3).

9. Inheritance and Population

Epidemiology (incidence/prevalence)

  • Italy (Friuli-Venezia Giulia, 2009–2017): incidence 0.89/100,000 person-years; prevalence 4.37/100,000; incidence increased over time (0.62 → 0.81 → 1.22 per 100,000 across successive 3-year periods) (vogrig2020epidemiologyofparaneoplastic pages 1-2).
  • United States (Olmsted County, 1987–2018): incidence 0.6/100,000 person-years; prevalence 5.4/100,000; incidence increased from 0.4 to 0.8 per 100,000 person-years comparing 1987–2002 vs 2003–2018 (shah2022populationbasedepidemiologystudy pages 1-3).
  • Consensus estimate in criteria paper: PNS occur in ~1 of 300 cancer patients and population incidence estimates range 1.6–8.9 per million person-years, suggesting underdiagnosis (graus2021updateddiagnosticcriteria pages 1-2).

Morbidity burden statistics

U.S. population-based study estimated 17,099 prevalent cases in the U.S. and predicted DALY burden 292,393 years for all U.S. PNS cases (shah2022populationbasedepidemiologystudy pages 1-3).

10. Diagnostics

Diagnostic criteria (2021 PNS-Care)

The 2021 consensus update defines three evidence levels (definite, probable, possible) using a PNS-Care Score that combines phenotype risk, antibody risk, cancer presence/absence, and follow-up time; except for opsoclonus-myoclonus, definite PNS requires high- or intermediate-risk antibodies (graus2021updateddiagnosticcriteria pages 1-2).

Antibody testing: performance and pitfalls (nationwide real-world data, 2024)

A nationwide Netherlands study (2016–2021) quantified real-world antibody test characteristics and emphasized PPV pitfalls in rare disease testing: - Abstract quote: “Sensitivity and specificity were high (>95%) to very high (>99%) for most tests in both serum and CSF. PPVs for several tests were moderate to poor, especially for serum testing of IA antibodies (25%–80%).” (Neurol Neuroimmunol Neuroinflamm; published 2024-11) (kerstens2024autoimmuneencephalitisand pages 1-2). - Serum CBA-only PPVs for selected surface antibodies were modest and improved with confirmatory tissue-based methods: NMDAR 69.7%, Caspr2 71.7%, GABABR 78.8%, LGI1 91.8%; with IHC confirmation these increased to 97.1%, 94.3%, 100%, 96.4% respectively (kerstens2024autoimmuneencephalitisand pages 2-4). - For a classical onconeural antibody example, anti-Yo PPV improved from 28.8% (immunoblot alone) to 77.8% (immunoblot + IIF) (kerstens2024autoimmuneencephalitisand pages 2-4).

CSF vs serum testing considerations

CSF can be more sensitive for some antibodies (e.g., NMDAR, KLHL11, GFAP, Ri) while for others serum may be more sensitive; importantly, commercial assays can miss CSF antibodies that tissue-based methods detect (e.g., LGI1 and Caspr2 CSF CBA false negatives with positive CSF IHC) (kerstens2024autoimmuneencephalitisand pages 2-4).

CSF/MRI inflammatory support

Population-based PNS definitions often rely on the presence of onconeural antibodies in serum/CSF together with evidence of inflammation such as CSF pleocytosis/OCBs or MRI features suggestive of encephalitis/myelitis (vogrig2020epidemiologyofparaneoplastic pages 1-2).

Imaging/tumor search and real-world implementation

Initial malignancy screening commonly uses whole-body CT and/or FDG-PET/CT with phenotype/antibody-directed targeted testing (e.g., testicular ultrasound; pelvic MRI for suspected teratoma) (vogrig2020epidemiologyofparaneoplastic pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14). If initial screening is negative, repeat tumor screening every 3–6 months initially and then every 6 months up to 4 years has been recommended in recent review guidance (marsili2023paraneoplasticneurologicalsyndromes pages 12-14).

Practical diagnostic workflow

Step Purpose Key actions/tests Evidence/pitfalls Notes on real-world implementation
1. Recognize a compatible syndrome Identify patients who warrant urgent PNS workup Assess for subacute/rapidly progressive neurologic syndromes; classify presentation as high-risk phenotype or possible intermediate-risk phenotype under 2021 PNS-Care framework; exclude direct cancer effects, infection, toxic-metabolic causes, treatment toxicity, stroke, and degenerative disease (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6, binks2022paraneoplasticneurologicalsyndromes pages 1-1, boldicke2023diagnosisandtreatment pages 4-5) PNS diagnosis is syndromic first, not antibody-first; no neurologic syndrome is exclusively paraneoplastic, so overcalling based on isolated antibody findings is a major pitfall (graus2021updateddiagnosticcriteria pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3) In practice, neurology-oncology review early in the course improves triage and helps decide whether to pursue full PNS-Care scoring and malignancy search immediately
2. Apply PNS-Care risk logic early Estimate likelihood of true paraneoplastic disease and prioritize workup urgency Combine phenotype risk, antibody risk category, presence/absence of cancer, and follow-up context using PNS-Care approach; note that definite PNS usually requires high- or intermediate-risk antibodies except opsoclonus-myoclonus (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria media 0aa3f63e) 2021 criteria replace “classical/non-classical” language with high-/intermediate-risk phenotypes and antibodies; probable and definite cases should both be managed urgently (graus2021updateddiagnosticcriteria pages 1-2, dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2) Helpful for standardization, but some real-world patients with likely PNS may still fall below probable/definite thresholds, so clinical judgment remains essential
3. Obtain paired serum and CSF Maximize diagnostic sensitivity and reduce false interpretation Send both serum and CSF for neuronal antibody testing plus routine CSF studies: cell count, protein, oligoclonal bands/IgG index; pair antibody testing with inflammatory markers and syndrome-specific studies (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, vogrig2020epidemiologyofparaneoplastic pages 1-2, boldicke2023diagnosisandtreatment pages 4-5) Serum-only testing can mislead; false positives are suggested by atypical presentations, very low titers, or antibodies found only in serum and not CSF; LGI1 is an exception where serum may be more sensitive (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, kerstens2024autoimmuneencephalitisand pages 2-4) A practical default is “serum + CSF together” at first lumbar puncture to avoid repeat procedures and delayed interpretation
4. Use confirmatory antibody methods, not single commercial assays alone Improve positive predictive value (PPV) and clinical specificity Prefer multistep testing with tissue-based confirmation (IHC/IIF) and/or orthogonal assays instead of relying on isolated immunoblot or CBA results (kerstens2024autoimmuneencephalitisand pages 1-2, kerstens2024autoimmuneencephalitisand pages 2-4) In the Netherlands nationwide study, specificity was usually high, but PPV was only modest for several rare-disease tests; serum CBA-only PPVs were 69.7% for NMDAR, 71.7% for CASPR2, 78.8% for GABABR, and 91.8% for LGI1, improving to 97.1%, 94.3%, 100%, and 96.4% with IHC confirmation; anti-Yo PPV improved from 28.8% with immunoblot alone to 77.8% with immunoblot+IIF (kerstens2024autoimmuneencephalitisand pages 2-4, kerstens2024autoimmuneencephalitisand pages 1-2) Commercial “line blot positive” results should not be acted on in isolation, especially for intracellular/onconeural antibodies in low-pretest-probability settings
5. Interpret antibodies by antigen class and cancer-risk category Link serology to mechanism, prognosis, and tumor search strategy Distinguish intracellular/high-risk antibodies from neuronal-surface antibodies; use high-risk antibodies to direct urgent tumor search and counseling; interpret lower-risk antibodies in syndrome context (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6, binks2022paraneoplasticneurologicalsyndromes pages 1-1, boldicke2023diagnosisandtreatment pages 4-5) High-risk antibodies have >70% cancer association; intermediate-risk 30%–70%; lower-risk <30%; intracellular antibodies are often markers of T-cell-mediated disease rather than directly pathogenic, whereas surface antibodies are more often directly pathogenic and treatment responsive (graus2021updateddiagnosticcriteria pages 1-2, graus2021updateddiagnosticcriteria pages 4-6, binks2022paraneoplasticneurologicalsyndromes pages 1-1) Reporting should include antigen, sample type, method, titer when available, and risk category—not just “positive/negative”
6. Perform core neurologic phenotyping studies Support syndrome definition and identify inflammatory evidence Obtain MRI brain/spine as indicated, EEG for encephalitic/seizure presentations, EMG/NCS for neuropathy/LEMS, and syndrome-specific testing (marsili2023paraneoplasticneurologicalsyndromes pages 14-15, blaes2021pathogenesisdiagnosisand pages 1-3) CSF pleocytosis, CSF-exclusive oligoclonal bands, and MRI inflammatory changes support autoimmune/paraneoplastic etiologies but are not specific (vogrig2020epidemiologyofparaneoplastic pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14) These studies often provide the “objective inflammation” needed to justify ongoing tumor search even before antibodies return
7. Search for occult malignancy at baseline Detect the causative tumor and satisfy diagnostic criteria Use whole-body CT and/or FDG-PET/CT; add targeted tests guided by phenotype/antibody, such as testicular ultrasound for anti-Ma2/KLHL11 or pelvic imaging for teratoma-associated syndromes (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, vogrig2020epidemiologyofparaneoplastic pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3) About 80% of patients have positive tumor screening at first assessment in one recent review summary; CT, ultrasound, MRI, and FDG-PET are complementary rather than mutually exclusive (marsili2023paraneoplasticneurologicalsyndromes pages 12-14) Baseline tumor search should be parallel with neurologic workup, not delayed until antibodies finalize
8. Repeat tumor screening when initial studies are negative Capture cancers that are initially occult If first malignancy screen is negative, repeat every 3–6 months initially, then every 6 months for up to 4 years, especially in patients with high-risk phenotypes/antibodies (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3) A common pitfall is stopping after one negative CT; many PNS precede tumor diagnosis, and delayed cancer detection is well recognized (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3) Build repeat imaging into the care plan at discharge so follow-up does not depend on ad hoc reassessment
9. Reassess discordant or low-probability cases Prevent misdiagnosis and unnecessary immunotherapy Revisit alternative diagnoses when syndrome is low-risk, no tumor is found, antibody is low-titer/serum-only, or phenotype-antibody pairing is atypical (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, kerstens2024autoimmuneencephalitisand pages 1-2) Mass testing in rare diseases lowers PPV; clinically irrelevant positives occur, particularly when ordering broad panels in nonspecific neurologic presentations (kerstens2024autoimmuneencephalitisand pages 1-2, kerstens2024autoimmuneencephalitisand pages 2-4) Multidisciplinary case conference is useful for “positive antibody, wrong phenotype” cases
10. Document diagnostic confidence and act on urgency Translate workup into management pathway Record phenotype, antibody class/risk, cancer status, inflammatory evidence, and final certainty level (possible/probable/definite); begin treatment/tumor-directed management without waiting for perfect certainty when suspicion is strong (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2) The 2021 framework was designed for care and research standardization, but delayed treatment worsens outcomes; probable PNS should not be considered low priority (graus2021updateddiagnosticcriteria pages 1-2, dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2) A practical final note in reports is whether the patient meets or approaches PNS-Care probable/definite thresholds and what further testing would change classification

Table: This table summarizes a practical stepwise diagnostic workflow for suspected paraneoplastic neurological syndromes, integrating the 2021 PNS-Care framework with real-world assay pitfalls and tumor-screening recommendations. It is useful as a concise clinical checklist for applying recent evidence to workup and implementation.

11. Outcome / Prognosis

Population-based outcomes and disability

PNS are rare but can produce high morbidity and mortality. The U.S. population-based cohort quantified a high DALY burden largely driven by years of life lost (shah2022populationbasedepidemiologystudy pages 1-3).

Prognostic associations (observational)

Antibody class and underlying malignancy type are repeatedly highlighted as major determinants of outcome, with intracellular/onconeural syndromes often less responsive to immunotherapy than surface-antibody syndromes (blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1).

12. Treatment

Principles

Treatment is centered on (i) rapid identification and control of the underlying tumor and (ii) prompt immunotherapy when appropriate (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3).

Immunotherapy options (common clinical practice)

First-line immunotherapy approaches commonly include IV corticosteroids, IVIG, and plasma exchange; second-line options commonly include rituximab and cyclophosphamide (marsili2023paraneoplasticneurologicalsyndromes pages 12-14).

ICI-era real-world immunosuppression utilization

In a multicenter real-world cohort of patients with solid tumors and paraneoplastic syndromes treated with ICIs (2015–2022), PNS-directed immunosuppressive therapy was required in 50% (55/109), including steroids (42%), IVIG (12%), rituximab (5%), and plasmapheresis (4%) (nassar2024clinicaloutcomesand pages 3-5).

Suggested MAXO terms (examples)

  • Antineoplastic therapy (MAXO:0000748) (tumor-directed)
  • Glucocorticoid therapy (MAXO term for corticosteroid therapy)
  • Intravenous immunoglobulin therapy (MAXO term)
  • Therapeutic plasma exchange (MAXO term)
  • Anti-CD20 monoclonal antibody therapy (rituximab; MAXO term)

(MAXO IDs should be validated in MAXO; the present evidence supports the interventions but not their MAXO identifiers.)

Clinical trials

No PNS-specific interventional trials were retrieved via the clinical-trials tool in this run; the evidence base in the provided sources is primarily observational and consensus-based (marsili2023paraneoplasticneurologicalsyndromes pages 12-14).

13. Prevention

Primary prevention

There are no established primary prevention strategies for “classic” PNS beyond cancer prevention/early cancer detection in general.

Secondary prevention / early detection

Because PNS can precede the tumor, the main secondary-prevention concept is systematic malignancy search at presentation and scheduled repeat screening when initial workup is negative (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3).

Prevention considerations in the ICI era

Real-world ICI cohorts suggest de novo PNS and PNS exacerbations occur early in the ICI course, supporting careful baseline assessment and early monitoring in high-risk patients (nassar2024clinicaloutcomesand pages 1-2, nassar2024clinicaloutcomesand pages 3-5).

14. Other Species / Natural Disease

No naturally occurring veterinary analogs or cross-species susceptibility data were identified in the current evidence set.

15. Model Organisms

No specific validated animal models of PNS were identified in the current evidence set. Mechanistic inference in the current sources is primarily from human clinical-immunologic observation and translational immunology (binks2022paraneoplasticneurologicalsyndromes pages 1-1, blaes2021pathogenesisdiagnosisand pages 1-3).

Recent developments and “latest research” highlights (prioritizing 2023–2024)

1) Standardization of diagnosis using PNS-Care: the 2021 criteria have become the contemporary diagnostic framework, replacing the 2004 criteria and formalizing risk-stratified phenotypes and antibodies (graus2021updateddiagnosticcriteria pages 1-2).

2) Real-world antibody testing performance and PPV pitfalls (2024 Netherlands nationwide study): despite high specificity, PPV can be modest in rare-disease settings and improves substantially with confirmatory tissue-based testing; this directly affects clinical implementation of broad commercial panels and helps mitigate misdiagnosis (kerstens2024autoimmuneencephalitisand pages 1-2, kerstens2024autoimmuneencephalitisand pages 2-4).

3) ICI-era real-world outcomes and safety (2024 multicenter JITC cohort): patients with paraneoplastic syndromes have been excluded from ICI trials; real-world evidence shows PNS exacerbations occur in 29% of pre-existing PNS patients and can prompt ICI interruption, while overall treatment-related adverse events were similar to matched PNS-free patients in a metastatic NSCLC subgroup (nassar2024clinicaloutcomesand pages 1-2, nassar2024clinicaloutcomesand pages 3-5).

Key statistics (quick reference)

  • Incidence: 0.89/100,000 person-years (Italy, 2009–2017) (vogrig2020epidemiologyofparaneoplastic pages 1-2); 0.6/100,000 person-years (U.S., 1987–2018) (shah2022populationbasedepidemiologystudy pages 1-3).
  • Prevalence: 4.37/100,000 (Italy) (vogrig2020epidemiologyofparaneoplastic pages 1-2); 5.4/100,000 (U.S.) (shah2022populationbasedepidemiologystudy pages 1-3).
  • Tumor association (Italy study): PNS developed in 1 in 334 cancers (vogrig2020epidemiologyofparaneoplastic pages 1-2).
  • Antibody profile (Italy study, Ab-positive): Yo 30%, Hu 26%, Ma2 22% (vogrig2020epidemiologyofparaneoplastic pages 1-2).
  • Diagnostic test pitfall statistic (Netherlands nationwide): serum CBA-only PPVs ~70–92% for several surface Abs; onconeuronal (e.g., Yo) PPV as low as 28.8% with immunoblot alone, improved with confirmatory methods (kerstens2024autoimmuneencephalitisand pages 2-4).

Antibody–phenotype–tumor association summary table

Antibody (common name; target) Antigen location PNS-Care risk category Common neurologic phenotypes Common tumor associations Notes on treatment responsiveness/prognosis
Anti-Hu / ANNA-1 (neuronal nuclear antigens/Hu) Intracellular High risk (>70% cancer association) Limbic encephalitis, encephalomyelitis, sensory neuronopathy; also high-risk CNS/PNS presentations Small-cell lung cancer (SCLC) most typical Intracellular-antigen syndromes are thought to be mainly T-cell mediated; antibodies are diagnostic markers rather than directly pathogenic, and responses to immunotherapy are often limited/variable compared with surface-antibody syndromes (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-Yo / PCA-1 (CDR2/CDR2L) Intracellular High risk Rapidly progressive cerebellar syndrome / paraneoplastic cerebellar degeneration Breast and ovarian/gynecologic cancers Typically associated with cerebellar syndrome; intracellular-antigen profile generally predicts poorer immunotherapy responsiveness and often substantial residual disability (boldicke2023diagnosisandtreatment pages 4-5, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-Ri / ANNA-2 (Nova) Intracellular High risk Opsoclonus-myoclonus-ataxia syndrome, brainstem/cerebellar syndromes Breast cancer; also ovarian cancer and SCLC reported with OMS High-risk onconeural marker; syndrome–tumor pairing helps direct cancer search. As an intracellular-antigen syndrome, prognosis is often driven by rapid recognition and tumor control (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15)
Anti-Ma2 / Ta (PNMA2) Intracellular High risk Limbic encephalitis, diencephalic/brainstem encephalitis, encephalomyelitis, cerebellar syndrome Testicular germ-cell tumors/seminoma most characteristic High cancer association; phenotype often strongly guides tumor search. Like other intracellular-antigen syndromes, pathogenesis is thought to be T-cell dominant and treatment response less robust than with surface-antibody disease (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-CV2 / CRMP5 Intracellular High risk Multifocal CNS/PNS syndromes, neuropathy, encephalitic/brainstem/cerebellar presentations Commonly lung cancer/thymoma in broader PNS literature summarized by reviews High-risk intracellular marker; often part of multifocal PNS presentations. Clinical course can be severe and requires aggressive tumor search plus immunotherapy/tumor treatment (graus2021updateddiagnosticcriteria pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-amphiphysin (AMPH) Intracellular/synaptic vesicle-associated High risk Stiff-person spectrum disorders; encephalomyelitis/other multifocal syndromes may occur Breast cancer and SCLC are classic associations in review literature Considered a high-risk antibody in the updated framework; some cases may show partial immunotherapy responsiveness, but cancer treatment remains central (graus2021updateddiagnosticcriteria pages 1-2, blaes2021pathogenesisdiagnosisand pages 1-3)
Anti-KLHL11 (Kelch-like protein 11) Intracellular High risk Brainstem encephalitis, cerebellar syndrome, hearing-related rhombencephalitic presentations Testicular seminoma Newly recognized biomarker highlighted in updated reviews; useful for directing tumor screening in men with brainstem/cerebellar syndromes (marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-DNER / Tr (DNER) Surface-associated neuronal protein Intermediate risk (30–70% cancer association) Rapidly progressive cerebellar syndrome Hodgkin lymphoma Representative intermediate-risk antibody; phenotype–tumor pairing is clinically useful. Surface/extracellular-associated antibodies are generally more treatment-responsive than classic intracellular onconeural syndromes, though data remain limited (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-GABA-B receptor (GABABR) Surface receptor Intermediate risk Limbic encephalitis, prominent seizures/intractable epilepsy SCLC commonly associated Surface-antibody disorder with clearer direct antibody pathogenicity and generally better responsiveness to immunotherapy than intracellular-antigen PNS; cancer screening is still essential (marsili2023paraneoplasticneurologicalsyndromes pages 12-14, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, devine2021paraneoplasticneurologicalsyndromes pages 1-2, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-AMPAR (AMPA receptor) Surface receptor Intermediate risk Limbic encephalitis Thymoma, lung or breast tumors can be associated in review literature Cell-surface antibody syndrome; often more immunotherapy-responsive than high-risk intracellular syndromes, though malignancy search remains mandatory (graus2021updateddiagnosticcriteria pages 1-2, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-NMDAR (NMDA receptor) Surface receptor Lower risk / not typically classified as high-risk PNS marker Encephalitis/psychiatric and seizure-predominant syndromes Ovarian teratoma; testicular germ-cell tumors also reported May be paraneoplastic or non-paraneoplastic. Surface-antibody mechanism supports direct pathogenicity and typically better response to immunotherapy than intracellular onconeural disorders (boldicke2023diagnosisandtreatment pages 4-5, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-LGI1 (leucine-rich glioma-inactivated 1) Surface/secreted synaptic protein Lower risk Faciobrachial dystonic seizures, autoimmune encephalitis/limbic encephalitis Often no tumor identified Usually not strongly cancer-associated; an important differential when evaluating suspected PNS. Surface-antibody disease is often immunotherapy responsive (boldicke2023diagnosisandtreatment pages 4-5, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)
Anti-CASPR2 (contactin-associated protein-like 2) Surface/paranodal membrane protein Lower risk Morvan syndrome, encephalitis/peripheral nerve hyperexcitability spectrum Thymoma can occur, but many cases are non-paraneoplastic Lower cancer risk than classic onconeural antibodies; often more responsive to immunotherapy than intracellular-antigen syndromes (boldicke2023diagnosisandtreatment pages 4-5, marsili2023paraneoplasticneurologicalsyndromes pages 14-15, binks2022paraneoplasticneurologicalsyndromes pages 1-1)

Table: This table summarizes representative PNS-associated antibodies by antigen location, 2021 PNS-Care risk category, typical neurologic phenotypes, tumor associations, and broad treatment/prognostic implications. It is useful for quickly linking syndrome presentation to antibody interpretation and malignancy search priorities.

URLs and publication dates (where available in evidence)

  • Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology & Neuroinflammation. 2021-07. https://doi.org/10.1212/nxi.0000000000001014 (graus2021updateddiagnosticcriteria pages 1-2)
  • Marsili L, et al. Paraneoplastic Neurological Syndromes of the CNS: Pathophysiology, Diagnosis, and Treatment. Biomedicines. 2023-05. https://doi.org/10.3390/biomedicines11051406 (marsili2023paraneoplasticneurologicalsyndromes pages 12-14)
  • Kerstens J, et al. Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes: A Nationwide Study on Epidemiology and Antibody Testing Performance. Neurology: Neuroimmunology & Neuroinflammation. 2024-11. https://doi.org/10.1212/NXI.0000000000200318 (kerstens2024autoimmuneencephalitisand pages 1-2)
  • Shah S, et al. Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology & Neuroinflammation. 2022-03. https://doi.org/10.1212/nxi.0000000000001124 (shah2022populationbasedepidemiologystudy pages 1-3)
  • Vogrig A, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. Journal of Neurology. Accepted 2019-09; published online 2019/2020. https://doi.org/10.1007/s00415-019-09544-1 (vogrig2020epidemiologyofparaneoplastic pages 1-2)
  • Nassar AH, et al. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal for ImmunoTherapy of Cancer. 2024-03. https://doi.org/10.1136/jitc-2023-008724 (nassar2024clinicaloutcomesand pages 1-2, nassar2024clinicaloutcomesand pages 3-5)

References

  1. (graus2021updateddiagnosticcriteria pages 1-2): Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo, Jean-Christophe G. Antoine, Virginie Desestret, Divyanshu Dubey, Bruno Giometto, Sarosh R. Irani, Bastien Joubert, Frank Leypoldt, Andrew McKeon, Harald Prüss, Dimitri Psimaras, Laure Thomas, Maarten J. Titulaer, Christian A. Vedeler, Jan J. Verschuuren, Josep Dalmau, and Jerome Honnorat. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Jul 2021. URL: https://doi.org/10.1212/nxi.0000000000001014, doi:10.1212/nxi.0000000000001014. This article has 780 citations.

  2. (binks2022paraneoplasticneurologicalsyndromes pages 1-1): Sophie Binks, Christopher Uy, Jerome Honnorat, and Sarosh R Irani. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Practical Neurology, 22:19-31, Sep 2022. URL: https://doi.org/10.1136/practneurol-2021-003073, doi:10.1136/practneurol-2021-003073. This article has 128 citations and is from a peer-reviewed journal.

  3. (vogrig2020epidemiologyofparaneoplastic pages 1-2): Alberto Vogrig, Gian Luigi Gigli, Samantha Segatti, Elisa Corazza, Alessandro Marini, Andrea Bernardini, Francesca Valent, Martina Fabris, Francesco Curcio, Francesco Brigo, Donatella Iacono, Paolo Passadore, Michele Rana, Jérôme Honnorat, and Mariarosaria Valente. Epidemiology of paraneoplastic neurological syndromes: a population-based study. Journal of Neurology, 267:26-35, Sep 2020. URL: https://doi.org/10.1007/s00415-019-09544-1, doi:10.1007/s00415-019-09544-1. This article has 223 citations and is from a domain leading peer-reviewed journal.

  4. (boldicke2023diagnosisandtreatment pages 4-5): T. Böldicke, I. Benhar, D. Chiu, J. Rhee, and L. N. G. Castro. Diagnosis and treatment of paraneoplastic neurologic syndromes. Antibodies, 12:50, Jul 2023. URL: https://doi.org/10.3390/antib12030050, doi:10.3390/antib12030050. This article has 27 citations.

  5. (marsili2023paraneoplasticneurologicalsyndromes pages 12-14): Luca Marsili, Samuel Marcucci, Joseph LaPorta, Martina Chirra, Alberto J. Espay, and Carlo Colosimo. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines, 11:1406, May 2023. URL: https://doi.org/10.3390/biomedicines11051406, doi:10.3390/biomedicines11051406. This article has 53 citations.

  6. (blaes2021pathogenesisdiagnosisand pages 1-3): Franz Blaes. Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes. Expert Review of Neurotherapeutics, 21:675-686, May 2021. URL: https://doi.org/10.1080/14737175.2021.1927713, doi:10.1080/14737175.2021.1927713. This article has 18 citations and is from a peer-reviewed journal.

  7. (nassar2024clinicaloutcomesand pages 3-5): Amin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh Naqash, Elad Sharon, Nicole R LeBoeuf, Alessio Cortellini, Andrea Malgeri, Shruti Gupta, Ahmad Al-Hader, Jeffrey A Sparks, Jenny Linnoila, Ole-Petter R Hamnvik, Tarek H Mouhieddine, Thomas Marron, Kaushal Parikh, Rana R McKay, Thomas Dilling, Toni K Choueiri, Elio Adib, Elie Najem, So Yeon Kim, and Guru Sonpavde. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal for Immunotherapy of Cancer, 12:e008724, Mar 2024. URL: https://doi.org/10.1136/jitc-2023-008724, doi:10.1136/jitc-2023-008724. This article has 8 citations and is from a domain leading peer-reviewed journal.

  8. (nassar2024clinicaloutcomesand pages 1-2): Amin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh Naqash, Elad Sharon, Nicole R LeBoeuf, Alessio Cortellini, Andrea Malgeri, Shruti Gupta, Ahmad Al-Hader, Jeffrey A Sparks, Jenny Linnoila, Ole-Petter R Hamnvik, Tarek H Mouhieddine, Thomas Marron, Kaushal Parikh, Rana R McKay, Thomas Dilling, Toni K Choueiri, Elio Adib, Elie Najem, So Yeon Kim, and Guru Sonpavde. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal for Immunotherapy of Cancer, 12:e008724, Mar 2024. URL: https://doi.org/10.1136/jitc-2023-008724, doi:10.1136/jitc-2023-008724. This article has 8 citations and is from a domain leading peer-reviewed journal.

  9. (graus2021updateddiagnosticcriteria pages 4-6): Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo, Jean-Christophe G. Antoine, Virginie Desestret, Divyanshu Dubey, Bruno Giometto, Sarosh R. Irani, Bastien Joubert, Frank Leypoldt, Andrew McKeon, Harald Prüss, Dimitri Psimaras, Laure Thomas, Maarten J. Titulaer, Christian A. Vedeler, Jan J. Verschuuren, Josep Dalmau, and Jerome Honnorat. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Jul 2021. URL: https://doi.org/10.1212/nxi.0000000000001014, doi:10.1212/nxi.0000000000001014. This article has 780 citations.

  10. (shah2022populationbasedepidemiologystudy pages 1-3): Shailee Shah, Eoin P. Flanagan, Pritikanta Paul, Carin Y. Smith, Sandra C. Bryant, Michelle F. Devine, Vanda A. Lennon, Andrew McKeon, Sean J. Pittock, and Divyanshu Dubey. Population-based epidemiology study of paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Mar 2022. URL: https://doi.org/10.1212/nxi.0000000000001124, doi:10.1212/nxi.0000000000001124. This article has 65 citations.

  11. (kerstens2024autoimmuneencephalitisand pages 1-2): Jeroen Kerstens, Marco W.J. Schreurs, Juna M. de Vries, Rinze F. Neuteboom, Juliette Brenner, Yvette S. Crijnen, Robin W. van Steenhoven, Marienke A.A.M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete, Anna E.M. Bastiaansen, Marie R. Vermeiren, Jan G.M.C. Damoiseaux, Henny G. Otten, Catharina J.M. Frijns, Bob Meek, Anouk C.M. Platteel, Alina van de Mortel, Cathérine C.S. Delnooz, Maarten A.C. Broeren, Marcel M. Verbeek, Erik I. Hoff, Sanae Boukhrissi, Suzanne C. Franken, Mariska M.P. Nagtzaam, Manuela Paunovic, Sharon Veenbergen, Peter A.E. Sillevis Smitt, and Maarten J. Titulaer. Autoimmune encephalitis and paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Nov 2024. URL: https://doi.org/10.1212/nxi.0000000000200318, doi:10.1212/nxi.0000000000200318. This article has 32 citations.

  12. (kerstens2024autoimmuneencephalitisand pages 2-4): Jeroen Kerstens, Marco W.J. Schreurs, Juna M. de Vries, Rinze F. Neuteboom, Juliette Brenner, Yvette S. Crijnen, Robin W. van Steenhoven, Marienke A.A.M. de Bruijn, Agnes van Sonderen, Marleen H. van Coevorden-Hameete, Anna E.M. Bastiaansen, Marie R. Vermeiren, Jan G.M.C. Damoiseaux, Henny G. Otten, Catharina J.M. Frijns, Bob Meek, Anouk C.M. Platteel, Alina van de Mortel, Cathérine C.S. Delnooz, Maarten A.C. Broeren, Marcel M. Verbeek, Erik I. Hoff, Sanae Boukhrissi, Suzanne C. Franken, Mariska M.P. Nagtzaam, Manuela Paunovic, Sharon Veenbergen, Peter A.E. Sillevis Smitt, and Maarten J. Titulaer. Autoimmune encephalitis and paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Nov 2024. URL: https://doi.org/10.1212/nxi.0000000000200318, doi:10.1212/nxi.0000000000200318. This article has 32 citations.

  13. (graus2021updateddiagnosticcriteria media 0aa3f63e): Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo, Jean-Christophe G. Antoine, Virginie Desestret, Divyanshu Dubey, Bruno Giometto, Sarosh R. Irani, Bastien Joubert, Frank Leypoldt, Andrew McKeon, Harald Prüss, Dimitri Psimaras, Laure Thomas, Maarten J. Titulaer, Christian A. Vedeler, Jan J. Verschuuren, Josep Dalmau, and Jerome Honnorat. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurology Neuroimmunology & Neuroinflammation, Jul 2021. URL: https://doi.org/10.1212/nxi.0000000000001014, doi:10.1212/nxi.0000000000001014. This article has 780 citations.

  14. (dimitrov2026paraneoplasticneurologicalsyndromes pages 1-2): Stoimen Dimitrov, Mihael Tsalta-Mladenov, Plamena Kabakchieva, Tsvetoslav Georgiev, and Silva Andonova. Paraneoplastic neurological syndromes: advances and future perspectives in immunopathogenesis and management. Antibodies, 15:8, Jan 2026. URL: https://doi.org/10.3390/antib15010008, doi:10.3390/antib15010008. This article has 2 citations.

  15. (marsili2023paraneoplasticneurologicalsyndromes pages 14-15): Luca Marsili, Samuel Marcucci, Joseph LaPorta, Martina Chirra, Alberto J. Espay, and Carlo Colosimo. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines, 11:1406, May 2023. URL: https://doi.org/10.3390/biomedicines11051406, doi:10.3390/biomedicines11051406. This article has 53 citations.

  16. (devine2021paraneoplasticneurologicalsyndromes pages 1-2): Michelle F. Devine, Naga Kothapalli, Mahmoud Elkhooly, and Divyanshu Dubey. Paraneoplastic neurological syndromes: clinical presentations and management. Therapeutic Advances in Neurological Disorders, Jan 2021. URL: https://doi.org/10.1177/1756286420985323, doi:10.1177/1756286420985323. This article has 102 citations and is from a peer-reviewed journal.

Artifacts

OpenScientist ▸
1. Disease Information
openscientist-autonomous 39 citations 2026-05-16T16:18:13.773934

1. Disease Information

Overview

Paraneoplastic neurological syndromes (PNS) are remote neurological complications of cancer that cannot be attributed to direct tumor invasion, metastases, infection, coagulopathy, or treatment side effects. They are mediated by immune responses initially directed against tumor-expressed antigens (onconeural antigens) that cross-react with antigens expressed in the nervous system. PNS can affect any level of the neuraxis—central, peripheral, and autonomic—and often involve multiple areas simultaneously.

As described in the literature: "Paraneoplastic neurologic disorders (PND) are remote medical complications of cancer that cannot be attributed to direct effects of the neoplasm or its metastases. PND are uncommon, disabling syndromes that have been recognized for more than 50 years" (PMID: 16635427). More recently: "PNSs are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability" (PMID: 41562781).

Key Identifiers

Database Identifier
ICD-10 G13.0 (Paraneoplastic neuromyopathy and neuropathy); G13.1 (Other systemic atrophy primarily affecting CNS in neoplastic disease); G73.1 (Lambert-Eaton syndrome in neoplastic disease)
ICD-11 8A45 (Paraneoplastic disorders of the nervous system)
MeSH D020361 (Paraneoplastic Syndromes, Nervous System)
Orphanet ORPHA:36388 (Paraneoplastic neurologic syndrome)
MONDO MONDO:0021081 (paraneoplastic neurological syndrome)
OMIM Not a single-gene Mendelian disorder; no dedicated OMIM entry

Common Synonyms and Alternative Names

  • Paraneoplastic neurologic disorders (PND)
  • Paraneoplastic neurological disease
  • Remote effects of cancer on the nervous system
  • Paraneoplastic autoimmune neurological syndromes
  • Immune-mediated paraneoplastic disorders
  • Specific subtypes: Paraneoplastic cerebellar degeneration (PCD), paraneoplastic encephalomyelitis, paraneoplastic limbic encephalitis, paraneoplastic sensory neuronopathy, Lambert-Eaton myasthenic syndrome (LEMS), paraneoplastic opsoclonus-myoclonus-ataxia syndrome (OMAS), paraneoplastic stiff-person syndrome

Information Sources

This report synthesizes aggregated disease-level information from published literature, clinical cohort studies, diagnostic criteria consensus documents, population-based registries, and systematic reviews.

2. Etiology

Disease Causal Factors

The primary cause of PNS is an aberrant anti-tumor immune response that cross-reacts with the nervous system. The fundamental mechanism involves tumor expression of proteins normally restricted to neurons (onconeural antigens). When tumor cells undergo somatic mutations, gene amplifications, or loss of heterozygosity in genes encoding these antigens, neoantigens are created that breach immune tolerance.

This has been directly demonstrated in anti-Yo paraneoplastic cerebellar degeneration: "The Yo autoantibodies are directed against the Yo antigens, aberrantly overexpressed by tumor cells with frequent somatic mutations and gene amplifications. The massive infiltration of these tumors by immune cells suggests that they are the site of the immune tolerance breakdown, leading to the destruction of Purkinje cells harboring the Yo antigens" (PMID: 38494293).

Similarly, in cancer-associated dermatomyositis (CAD), somatic mutations and loss of heterozygosity in autoantibody-related genes (TRIM33/TIF1-γ, MORC3/NXP2, CHD4/Mi2, IFIH1/MDA5) were detected in the majority of tumors (PMID: 41290487). The cancer risk conferred by specific autoantibodies quantifies this association: anti-TIF1-γ had a standardized incidence ratio (SIR) of 17.28 (95% CI 11.94–24.14) for cancer, and anti-NXP2 had SIR 8.14 (95% CI 1.63–23.86) (PMID: 29178913).

Risk Factors

Genetic Risk Factors

  • HLA-DQ2 and HLA-DR3: Significantly overrepresented in patients with Hu-associated PNS compared to healthy controls: "This study indicates an association between Hu-PNS and presence of HLA-DQ2 and HLA-DR3, which supports a role for CD4(+) T cells in the pathogenesis of Hu-PNS" (PMID: 20547426).
  • HLA-KIR axis: Suggested involvement in anti-NMDAR encephalitis: "Our observations for the first time suggest that the HLA-KIR axis might be involved in anti-NMDAR encephalitis. While the genetic risk conferred by the identified polymorphisms appears small, a role of this axis in the pathophysiology of this disease appears highly plausible" (PMID: 39050850).

Environmental and Oncologic Risk Factors

  • Underlying malignancy is the primary risk factor. Specific tumor types confer different risks:
  • Small cell lung cancer (SCLC): anti-Hu, anti-VGCC (LEMS), anti-CRMP5, anti-SOX1
  • Ovarian teratoma: anti-NMDAR encephalitis
  • Breast and ovarian cancer: anti-Yo
  • Testicular seminoma: anti-KLHL11, anti-Ma2
  • Thymoma: multiple antibody associations
  • Neuroblastoma (children): opsoclonus-myoclonus syndrome
  • Age: Median age ~63 years for most PNS; anti-NMDAR encephalitis peaks in younger patients (mean 23 years)
  • Sex: Overall male predominance (57%) in general PNS cohorts (PMID: 41573575); female predominance in anti-NMDAR encephalitis (79%) and anti-Yo PNS
  • Immune checkpoint inhibitor (ICI) therapy: ICI-related PNS is an emerging risk factor, with 72.2% of patients developing neurological symptoms within 6 months of ICI initiation (PMID: 40042691)

Protective Factors

  • Early tumor detection and removal: Ovarian teratoma removal improves anti-NMDAR encephalitis recovery rate by 25% (PMID: 41633558)
  • Paradoxical immune surveillance: The anti-tumor immune response in paraneoplastic LEMS appears to confer improved cancer survival compared to non-LEMS SCLC (median 17 vs 7 months) (PMID: 31831596). Spontaneous cancer regression has been documented in LEMS-associated SCLC (PMID: 37680668).

Gene-Environment Interactions

The interplay between HLA susceptibility alleles and tumor-specific somatic mutations represents the key gene-environment interaction in PNS. HLA class II molecules (HLA-DQ2/DR3) present tumor-derived neopeptides to CD4+ T cells, amplifying both anti-tumor and autoimmune responses. The HLA-KIR axis modulates NK cell activity and may influence the threshold for autoimmune breakthrough in susceptible individuals.

3. Phenotypes

PNS encompass a wide spectrum of neurological phenotypes. The 2021 PNS-Care criteria classify them into high-risk and intermediate-risk phenotypes for cancer association.

High-Risk Phenotypes (>70% associated with cancer)

Phenotype HPO Term Frequency Key Features
Rapidly progressive cerebellar syndrome (PCD) HP:0002073 (Progressive cerebellar ataxia), HP:0001251 (Cerebellar ataxia) ~29% of PNS Rapidly progressive gait and limb ataxia, dysarthria, nystagmus; most common PNS phenotype in validation cohorts (PMID: 39321395)
Limbic encephalitis HP:0002383 (Encephalitis), HP:0002354 (Memory impairment) ~8–35% of PNS Memory impairment, seizures, psychiatric symptoms, altered consciousness
Encephalomyelitis HP:0100806 (Encephalomyelitis) Variable Multifocal CNS involvement
Subacute sensory neuronopathy HP:0009830 (Peripheral neuropathy), HP:0002936 (Distal sensory impairment) Variable Asymmetric sensory loss, pain, sensory ataxia
Lambert-Eaton myasthenic syndrome HP:0003348 (Lambert-Eaton myasthenic syndrome), HP:0003324 (Generalized muscle weakness) ~13% of ICI-PNS Proximal weakness (especially legs), autonomic dysfunction, hyporeflexia

Intermediate-Risk Phenotypes (30–70% associated with cancer)

Phenotype HPO Term Key Features
Brainstem encephalitis HP:0100253 (Brainstem dysfunction) Diplopia, vertigo, bulbar symptoms; ~14% of PNS
Opsoclonus-myoclonus syndrome HP:0040087 (Opsoclonus), HP:0001336 (Myoclonus) Rapid eye movements, myoclonus, ataxia; in children often with neuroblastoma
Stiff-person syndrome HP:0002063 (Rigidity) Progressive rigidity, spasms of trunk and limbs
Autoimmune retinopathy HP:0000572 (Visual loss), HP:0000662 (Nyctalopia) Visual loss, photopsias, ring scotoma

Anti-NMDAR Encephalitis (Special Subtype)

Anti-NMDAR encephalitis deserves special mention as the most common form of autoimmune encephalitis. It predominantly affects young women (mean age 23 years, 79% female) and follows a stereotyped clinical sequence: psychiatric symptoms → seizures → movement disorders → autonomic dysfunction → decreased consciousness. In a large international cohort (n=702): "Most patients (96%; 672/702) had received first-line immunotherapy, and 38% (233/615) showed improvement within two weeks. One year after diagnosis, 80% (517/644) had a favourable functional outcome (mRS≤2). At three years, 73% (203/278) had resumed work/school" (PMID: 41488792).

Anti-Ri PNS

A systematic review of 85 cases found: median age 61 years, 78.6% female. "At the disease onset, ataxia was the most prevalent neurological symptom (70.6%). Twenty-six patients (30.6%) developed opsoclonus, and 22.4% developed myoclonus. Breast cancer was frequently observed in female patients (65.2%), whereas lung cancer was more common in male patients (38.9%)" (PMID: 41894019).

Overall Clinical Profile

In a cohort of 114 PNS patients from Northern China (PMID: 41573575): median age 63 years, 57% males. Muscle weakness was most common (53.5%), followed by seizures and altered consciousness. Associated tumors in 66.7%, mainly lung (65.8%) and breast (9.2%). Antibodies detected in 79.8%.

Quality of Life Impact

PNS have devastating effects on quality of life. Intracellular antigen syndromes frequently progress to wheelchair dependence. Even patients with treatable surface antibody syndromes may have prolonged recovery and residual cognitive/psychiatric sequelae.

{{figure:pns_overview_figure.png|caption=Overview of PNS antibody classification, associated phenotypes, and their frequencies based on the 2021 PNS-Care criteria}}

4. Genetic/Molecular Information

Autoantibody Target Genes

PNS are not caused by germline mutations; instead, the disease involves somatic mutations in tumor cells affecting genes encoding neuronal antigens. Key autoantigen genes:

Gene Protein Antibody Name HGNC ID Subcellular Location
ELAVL4 HuD Anti-Hu/ANNA-1 HGNC:3314 Intracellular (nuclear)
CDR2/CDR2L Cerebellar degeneration-related protein 2 Anti-Yo/PCA-1 HGNC:1805 Intracellular (cytoplasmic)
NOVA1/NOVA2 Nova proteins Anti-Ri/ANNA-2 HGNC:7886 Intracellular (nuclear)
DPYSL5 CRMP5 Anti-CV2/CRMP5 HGNC:3017 Intracellular (cytoplasmic)
AMPH Amphiphysin Anti-amphiphysin HGNC:471 Intracellular (synaptic)
PNMA2 Ma2 antigen Anti-Ma2 HGNC:9158 Intracellular (nuclear)
GRIN1 NMDA receptor NR1 subunit Anti-NMDAR HGNC:4584 Cell surface
LGI1 Leucine-rich glioma inactivated 1 Anti-LGI1 HGNC:6572 Cell surface
CNTNAP2 CASPR2 Anti-CASPR2 HGNC:13830 Cell surface
GRIA1/GRIA2 AMPA receptor subunits Anti-AMPAR HGNC:4571 Cell surface
GABBR1 GABA-B receptor 1 Anti-GABA-B HGNC:4070 Cell surface
CACNA1A P/Q-type VGCC Anti-VGCC HGNC:1388 Cell surface
KLHL11 Kelch-like protein 11 Anti-KLHL11 HGNC:29041 Intracellular
SOX1 SOX1 Anti-SOX1/AGNA HGNC:11189 Intracellular (nuclear)

Somatic Variants in Tumors

In anti-Yo PCD, frequent somatic mutations and gene amplifications in CDR2/CDR2L genes have been demonstrated in associated tumors (PMID: 38494293). In cancer-associated dermatomyositis, "Somatic mutations and loss of heterozygosity (LOH) in autoantibody-related genes as tripartite motif containing 33... MORC family CW-type zinc finger 3 (MORC3), Chromodomain Helicase DNA Binding Protein 4, and IFIH1... were detected in the majority of tumours" (PMID: 41290487).

HLA Genetic Susceptibility

  • HLA-DQ2/DR3: Confer susceptibility to Hu-PNS (PMID: 20547426)
  • HLA-KIR axis: Suggested involvement in anti-NMDAR encephalitis with small genetic risk (PMID: 39050850)

Epigenetic and Chromosomal Information

Limited direct evidence exists for epigenetic modifications specific to PNS. Tumor-intrinsic epigenetic changes likely contribute to aberrant expression of onconeural antigens. No chromosomal abnormalities are characteristic of PNS per se, though tumor-associated amplifications may affect autoantigen loci.

5. Environmental Information

Environmental Factors

No specific environmental toxins have been directly linked to PNS causation. The primary trigger is the presence of a tumor expressing onconeural antigens. Factors contributing to cancer risk (smoking for SCLC) indirectly increase PNS risk.

Immune Checkpoint Inhibitor Exposure

ICI therapy is an increasingly important iatrogenic trigger. In a systematic review of 108 ICI-PNS patients: "The most frequently associated tumors included lung cancer, melanoma, and Merkel cell carcinoma, and 72.2% of patients developed neurological symptoms within 6 months after ICIs treatment" (PMID: 40042691). FAERS database analysis revealed a median onset of 30 days after ICI initiation (PMID: 41972167).

Infectious Agents

Herpes simplex virus (HSV): Post-HSV encephalitis autoimmune encephalitis is a recognized entity, with 89.3% being anti-NMDAR encephalitis (PMID: 40780589). Various viral prodromal illnesses have also been reported preceding childhood anti-NMDAR encephalitis and OMAS.

6. Mechanism / Pathophysiology

The Paraneoplastic Paradigm: From Tumor to Neuronal Destruction

The pathogenic cascade follows a multi-step process:

TUMOR GENETIC CHANGES
  (somatic mutations, gene amplifications, LOH in autoantigen genes)
↓
ABERRANT ANTIGEN EXPRESSION
  (tumor cells overexpress neuronal-restricted proteins)
↓
IMMUNE TOLERANCE BREAKDOWN
  (HLA-mediated antigen presentation → T cell priming)
↓
CROSS-REACTIVE AUTOIMMUNITY
  (immune effectors recognize shared antigens on neurons)
↓
NEUROLOGICAL DYSFUNCTION
  (irreversible neuronal death OR reversible synaptic dysfunction)

Two Immunopathogenic Pathways

This dual classification represents the most important mechanistic insight in PNS:

Pathway 1: T-cell mediated (Intracellular antigens) — "Disorders accompanied by autoantibody markers of neural peptide-specific cytotoxic effector T cells [such as anti-neuronal nuclear antibody type 1 (ANNA-1, aka anti-Hu), Purkinje cell antibody type 1 (PCA-1, aka anti-Yo) and CRMP-5 IgG] are generally poorly responsive to immunotherapy" (PMID: 21938556). CD8+ cytotoxic T lymphocytes infiltrate the nervous system and directly kill neurons via perforin/granzyme and Fas/FasL pathways, causing irreversible neuronal loss.

  • GO terms: GO:0006955 (immune response), GO:0001913 (T cell mediated cytotoxicity), GO:0006915 (apoptotic process)
  • Cell types: CL:0000910 (cytotoxic T cell), CL:0000540 (neuron), CL:0000121 (Purkinje cell)

Pathway 2: Antibody-mediated (Surface antigens) — "Disorders accompanied by neural plasma membrane-reactive autoantibodies [the effectors of synaptic disorders, which include antibodies targeting voltage-gated potassium channel (VGKC) complex proteins, NMDA and GABA-B receptors] generally respond well to early immunotherapy" (PMID: 21938556). Pathogenic IgG antibodies bind to extracellular epitopes, causing receptor cross-linking and internalization, complement activation, or functional blockade.

  • GO terms: GO:0019724 (B cell mediated immunity), GO:0007268 (chemical synaptic transmission)
  • Cell types: CL:0000236 (B cell), CL:0000786 (plasma cell)

{{figure:pns_mechanism_figure.png|caption=Pathogenic mechanism overview showing the two immunopathogenic pathways in PNS: T-cell mediated (intracellular antigens) and antibody-mediated (surface antigens)}}

Anti-NMDAR Encephalitis: Synaptic and Circuit Dysfunction

In mouse passive-transfer models, anti-GluN1 autoantibodies caused "pronounced functional coupling/clustering between hippocampal neurons, pathological hub-like properties, hypersynchrony despite reduced baseline activity, and altered network architecture with irregular neuronal ensembles" (PMID: 41917496). Importantly, treatment with SGE-301 (an NMDAR positive allosteric modulator) reversed memory deficits, NMDAR cluster reduction, and LTP impairment: "An oxysterol biology-based PAM of NMDARs is able to reverse the synaptic and memory deficits" (PMID: 34903638).

LEMS: Presynaptic Calcium Channel Dysfunction

Autoantibodies against P/Q-type VGCCs reduce calcium influx at presynaptic terminals, impairing acetylcholine release at the neuromuscular junction. This is demonstrated by low CMAP amplitudes with characteristic post-exercise facilitation (≥60% increment).

Somatic Mutations as the Universal Trigger

A unifying mechanistic principle emerges: somatic mutations in autoantigen genes within tumors create neoantigens that trigger cross-reactive autoimmunity. This "paraneoplastic paradigm" has been demonstrated in: 1. Anti-Yo PCD: CDR2/CDR2L somatic mutations and gene amplifications (PMID: 38494293) 2. Cancer-associated dermatomyositis: Somatic mutations and LOH in TRIM33, MORC3, CHD4, IFIH1 (PMID: 41290487)

Molecular Profiling

  • Neurofilament light chain (NfL): Elevated in CSF/serum in PNS, serving as a biomarker of neuronal injury. In pediatric OMS, CSF NfL was elevated +83% vs controls and decreased by 60% with treatment (PMID: 24342231).
  • PhIP-Seq: Novel phage display immunoprecipitation-sequencing enables unbiased antibody discovery (PMID: 41562781)

7. Anatomical Structures Affected

Organ Level

System Primary Structures UBERON Terms
Central Nervous System Cerebellum, hippocampus, amygdala, brainstem, spinal cord, cortex UBERON:0002037 (cerebellum), UBERON:0002421 (hippocampal formation), UBERON:0002298 (brainstem)
Peripheral Nervous System Dorsal root ganglia, peripheral nerves, neuromuscular junction UBERON:0000044 (dorsal root ganglion), UBERON:0000473 (neuromuscular junction)
Autonomic Nervous System Sympathetic/parasympathetic ganglia, enteric nervous system UBERON:0002410 (autonomic nervous system)
Visual System Retina (photoreceptors, bipolar cells) UBERON:0000966 (retina)

Tissue and Cell Level

Syndrome Cell Populations Targeted CL Terms
PCD Purkinje cells CL:0000121
Limbic encephalitis Hippocampal pyramidal neurons CL:0000598
Sensory neuronopathy Dorsal root ganglion sensory neurons CL:0000101
LEMS Motor nerve terminals (presynaptic) CL:0000100
Stiff-person syndrome GABAergic interneurons CL:0000617
CAR Photoreceptors CL:0000210
MAR ON-bipolar cells CL:0000748

Subcellular Level

  • Cell surface receptors: NMDA receptor complex (GO:0017146), VGCC complex (GO:0005891), GABA-B receptor (GO:0008328)
  • Postsynaptic density: GO:0014069
  • Presynaptic active zone: GO:0048786 (affected in LEMS)
  • Nucleus: GO:0005634 (Hu/ANNA-1 and Ri/ANNA-2 antigens)

Localization

PNS typically show bilateral involvement, though asymmetry may occur, particularly in early-stage sensory neuronopathy and limbic encephalitis.

8. Temporal Development

Onset

  • Typical age: Highly variable by subtype. Anti-NMDAR encephalitis: mean 23 years (PMID: 41488792). Pediatric OMAS: median 18–36 months (PMID: 41871563). Most other subtypes: 5th–7th decade (median 58–66 years).
  • Onset pattern: Subacute in the majority of cases (85.7%) (PMID: 29355452); idiopathic anti-Ma2 cases may have more insidious onset (PMID: 41499721).
  • Neurological symptoms precede cancer diagnosis in ~89% of patients, with a median lag of 15 weeks to tumor detection (PMID: 29355452). For anti-Ri PNS, the median interval was 1.5 months (PMID: 41894019).

Progression

  • Intracellular antigen PNS: Rapidly progressive with irreversible neuronal loss; wheelchair dependence occurs significantly faster with intracellular antibodies (PMID: 26414229)
  • Surface antigen PNS: More variable; 80% of anti-NMDAR encephalitis patients achieve favorable outcome at one year (PMID: 41488792)
  • LEMS: Chronic, often stable course; NT-LEMS survival similar to general population (PMID: 31831596)

Critical Periods

Early immunotherapy within weeks of symptom onset is critical for optimal outcomes. "Probable and definite PNS should be managed with equal urgency" (PMID: 41562781). Cancer may emerge years after initial PNS presentation, as demonstrated by a case of cancer detection after a 9-year course of LEMS (PMID: 37507235).

9. Inheritance and Population

Epidemiology

PNS are rare disorders:

Syndrome Prevalence Source
LEMS 0.3/100,000 (global mean); 2.6–3.3/million (US VA); 2.7/million (Japan, 95% CI 1.9–3.5) PMID: 40034005, PMID: 27997683, PMID: 36110924
Anti-NMDAR encephalitis ~1.5/million estimated Population studies
PNS overall ~1/10,000 cancer patients Rising with ICI use (PMID: 41562781)

PNS antibody testing diagnostic yield in suspected cases was only 7–8% (PMID: 41811514), emphasizing the importance of appropriate clinical selection.

Inheritance

PNS are not inherited. They are multifactorial, resulting from complex interactions between tumor genetics, host immune genetics (HLA alleles), and environmental triggers. No familial recurrence or Mendelian inheritance pattern has been established.

Population Demographics

  • Sex ratio: Variable by antibody type:
  • P-LEMS: 78.6% male; AI-LEMS: 68.8% female (PMID: 36110924)
  • Anti-NMDAR: 79% female (PMID: 41488792)
  • Anti-Ri: 78.6% female (PMID: 41894019)
  • Anti-Ma2: 71.4% male (PMID: 41499721)
  • Geographic distribution: Worldwide; no clear endemic regions. Higher reporting from specialized centers in Europe, North America, and Japan.

{{figure:pns_comprehensive_summary.png|caption=Comprehensive summary showing antibody-cancer associations, treatment response rates, age of onset distributions, and LEMS survival data across PNS subtypes}}

10. Diagnostics

The 2021 PNS-Care Diagnostic Criteria

The 2021 updated criteria (PMID: 34006622) replaced the 2004 framework: "The panel proposed to substitute classical syndromes with the term high-risk phenotypes for cancer and introduce the concept of intermediate-risk phenotypes. The term onconeural antibody was replaced by high risk (>70% associated with cancer) and intermediate risk (30%-70% associated with cancer) antibodies."

The PNS-Care Score combines clinical phenotype risk level, antibody type, cancer presence, and follow-up duration to classify: - Definite PNS: Score ≥8 - Probable PNS: Score 6–7 - Possible PNS: Score 4–5

In validation: "The 2021 PNS criteria definite/probable categorization (PNS-CARE score ≥ 6) had a sensitivity of 95%" (PMID: 39321395). Most common antibodies: PCA1/Yo-IgG (17%), KLHL11-IgG (16%), CRMP5-IgG (14%); most common phenotypes: rapidly progressive cerebellar syndrome (29%), brainstem encephalitis (14%), limbic encephalitis (8%).

Laboratory Tests

Test Role
Serum/CSF neural antibody panel (CBA, immunoblot, TBA) Diagnosis and antibody-risk classification
CSF analysis (cell count, protein, oligoclonal bands) CSF inflammation in 63% of ICI-PNS (PMID: 40042691)
Serum NfL Neuronal injury biomarker; prognostic role
Serum tumor markers (NSE, ProGRP, CA-125, AFP) Elevated in 44% of patients (PMID: 29355452)

Imaging and Electrophysiology

  • Brain MRI: FLAIR hyperintensities in limbic regions, cerebellar atrophy, brainstem lesions
  • PET-CT: Critical for occult tumor detection
  • EMG/NCS: Diagnostic for LEMS (low CMAP with ≥60% post-exercise increment)
  • EEG: Diffuse slowing, extreme delta brush in anti-NMDAR encephalitis
  • ERG: Abnormal in paraneoplastic retinopathy

Differential Diagnosis

Alternative diagnoses are common during PNS workup. In a population-based study of 878 patients tested for PNS antibodies, alternative diagnoses were identified in 661 (75%), including degenerative (36%), autoimmune (17%), and vascular (14%) conditions for CNS presentations (PMID: 41811514).

Genetic Testing

Genetic testing is not routinely indicated for PNS diagnosis, as PNS are acquired autoimmune conditions. HLA typing may have research utility.

11. Outcome/Prognosis

Survival and Mortality

Subtype Outcome Evidence
General PNS Age <65, CNS involvement, immunotherapy = favorable; SCLC, high-risk antibodies = adverse PMID: 41573575: "Age < 65 years, CNS involvement and immunotherapy are relevant to favorable short-term outcome. SCLC and high-risk antibodies are adverse factors of long-term survival in PNS."
ICI-PNS Mortality 29% (risk-antibody group), 17% (unknown-risk), 10% (antibody-negative) PMID: 41488641
LEMS NT-LEMS: normal survival; SCLC-LEMS: improved vs non-LEMS SCLC (17 vs 7 mo median) PMID: 31831596: "Survival was similar to that of the general population in 65 patients with NT-LEMS. Tumor survival was significantly longer in 81 patients with SCLC-LEMS compared to patients with non-LEMS SCLC (overall median survival 17 vs 7.0 months)"
Anti-NMDAR 80% favorable outcome (mRS≤2) at 1 year; 73% return to school/work by 3 years PMID: 41488792

NEOS2 Prognostic Score

For anti-NMDAR encephalitis, the NEOS2 score uses age, treatment delay, movement disorders, ICU requirement, and CSF leucocyte count to predict outcomes with AUC of 80% (95% CI 75–86%). Higher age (OR 0.35), treatment delay (OR 0.49), movement disorders (OR 0.32), ICU requirement (OR 0.34), and increased CSF leucocyte count (OR 0.65) independently predicted poorer outcomes (PMID: 41488792).

Prognostic Biomarkers

  • Antibody type: Single most important prognostic variable
  • NfL: Elevated levels correlate with neuronal injury severity; reduction with treatment predicts response (PMID: 24342231; PMID: 39307617)

12. Treatment

Dual Treatment Strategy

Management requires: 1. Tumor treatment — removal of the antigenic source 2. Immunotherapy — suppression of the autoimmune response

First-Line Immunotherapy

Treatment MAXO Term Notes
IV methylprednisolone MAXO:0000750 (Corticosteroid therapy) Mainstay (90.9% of ICI-PNS) (PMID: 40042691)
IV immunoglobulin (IVIg) MAXO:0000376 (Intravenous immunoglobulin therapy) Second most common
Plasma exchange (PLEX) MAXO:0001078 (Plasmapheresis) Especially effective for surface antibody PNS

Second-Line Immunotherapy

  • Rituximab (MAXO:0001298): Anti-CD20 B-cell depletion; "Rituximab independently predicted better outcomes" in post-HSVE autoimmune encephalitis (PMID: 40780589)
  • Cyclophosphamide: Broad immunosuppression for refractory cases

Symptomatic and Specific Treatments

  • 3,4-Diaminopyridine (amifampridine): For LEMS; 78% of patients improved (PMID: 27997683)
  • Telitacicept (BAFF/APRIL inhibitor): Promising in refractory LEMS (PMID: 41291493)

Surgical Interventions

  • Tumor resection (MAXO:0000004): Critical; early ovarian teratoma removal improves anti-NMDAR encephalitis recovery by 25% (PMID: 41633558)

Treatment Response by Antibody Category

Category Response Key Principle
Intracellular (Hu, Yo, Ri, CV2) Poor (<30% improve) Irreversible neuronal death; early treatment may stabilize
Surface (NMDAR, LGI1, GABA-B) Good (>70% improve) Reversible synaptic dysfunction; responds to immunotherapy
VGCC (LEMS) Moderate-good 3,4-DAP + immunotherapy + tumor treatment

"Patients with cell surface antibodies respond better to immunotherapies compared to those with intracellular antigen targets" (PMID: 38183975).

Experimental Therapeutics

  • NMDAR positive allosteric modulators: SGE-301 reversed antibody-mediated deficits in mice: "An oxysterol biology-based PAM of NMDARs is able to reverse the synaptic and memory deficits" (PMID: 34903638)
  • Intrathecal methotrexate/dexamethasone: For refractory anti-NMDAR encephalitis (PMID: 39859226)
  • Anti-FcRn antibodies (efgartigimod): Under investigation for antibody-mediated PNS subtypes

ICI-Related PNS Considerations

ICI discontinuation is generally recommended. However, durvalumab + chemotherapy may be tolerated in pre-existing LEMS: "ICI in combination with platinum doublet chemotherapy is still challenging but may be a treatment option for ES-SCLC patients complicated with PNS of LEMS" (PMID: 36896371).

Pre-treatment screening is recommended: "Pre-treatment screening for PNS-related antibodies is recommended, as it may facilitate early warning, identify high-risk patients, and help prevent autoimmune-related diseases caused by excessive immune modulation" (PMID: 41488641).

13. Prevention

Primary Prevention

No specific primary prevention exists for PNS. Cancer prevention strategies (smoking cessation for SCLC) indirectly reduce PNS risk.

Secondary Prevention (Early Detection)

  • PNS as cancer early warning: Neurological symptoms precede cancer diagnosis in ~89% of cases
  • Prompt antibody testing in patients with suggestive phenotypes
  • PNS-Care Score to stratify risk and guide tumor screening intensity
  • Pre-ICI antibody screening may identify high-risk patients (PMID: 41488641)

Tertiary Prevention

  • Early, aggressive immunotherapy to prevent irreversible neuronal loss
  • Ongoing tumor surveillance (cancer may emerge years later)
  • Long-term immunosuppression in relapsing disorders
  • Rehabilitation and supportive care

14. Other Species / Natural Disease

Comparative Biology

PNS-like syndromes are not extensively documented in veterinary medicine as naturally occurring diseases. Paraneoplastic neuropathies have been reported in dogs (NCBI Taxon: 9615) and cats (NCBI Taxon: 9685) in association with various neoplasms.

Conservation of Target Antigens

Key autoantigen targets are highly conserved across mammalian species: NMDA receptor subunits (GRIN1), VGCC subunits (CACNA1A), CDR2 orthologs, and ELAVL4 (HuD) are conserved across vertebrates, facilitating translational research.

Zoonotic Potential

Not applicable — PNS are autoimmune, not infectious.

15. Model Organisms

Anti-NMDAR Encephalitis Passive Transfer Model (Mouse)

The most extensively characterized PNS animal model. Using passive transfer of patient monoclonal anti-GluN1 autoantibodies: "Using a mouse model with passive-transfer of patient's monoclonal anti-GluN1-autoantibodies, we performed two-photon in vivo recordings of spontaneous dynamics under light anesthesia in CA1 microcircuits, a key hippocampal area for memory processing" (PMID: 41917496).

Key findings: hippocampal neuronal hypercoupling, pathological hub-like properties, hypersynchrony despite reduced baseline activity, memory deficits reversible by NMDAR PAM (SGE-301) (PMID: 34903638).

Phenotype recapitulation: Good for synaptic/memory dysfunction; limited for the full clinical syndrome (seizures, dyskinesias, autonomic dysfunction less pronounced).

Other Models

Model Application Limitations
Anti-NCAM1 passive transfer (mouse) Demonstrated pathogenic potential (PMID: 41694384) Early characterization
LEMS IgG passive transfer (rat) Demonstrates VGCC antibody pathogenicity at NMJ Transient; requires repeated injections
HEK293 cell-based assays Gold standard for antibody detection; KLHL11-abs detected in 32 patients by CBA (PMID: 31953318) Diagnostic tool, not disease model
Neuronal cell cultures/organoids Receptor internalization studies Lacks systemic immune context

Resources

  • MGI (Mouse Genome Informatics): Models for Grin1, Cacna1a, and other autoantigen gene knockouts
  • IMPC: Phenotyping data for autoantigen gene mutants
  • Cellosaurus: Cell lines expressing neural antigens

Mechanistic Model

┌─────────────────────────────────────────────────────────────────────┐
│                    THE PARANEOPLASTIC CASCADE                       │
├─────────────────────────────────────────────────────────────────────┤
│  STEP 1: TUMOR GENETIC CHANGES                                     │
│  ├── Somatic mutations in CDR2 (Yo), ELAVL4 (Hu), TRIM33, etc.   │
│  ├── Gene amplifications and LOH                                    │
│  └── Neoantigen creation                                           │
│           ↓                                                         │
│  STEP 2: IMMUNE TOLERANCE BREAKDOWN                                │
│  ├── HLA-DQ2/DR3-mediated antigen presentation                    │
│  ├── Massive tumor immune infiltration                             │
│  └── CD4+ T cell priming → B cell help + CD8+ CTL activation      │
│           ↓                                                         │
│  STEP 3: CROSS-REACTIVE AUTOIMMUNITY (2 PATHWAYS)                 │
│  ┌───────────────────────┬──────────────────────────────┐          │
│  │ PATHWAY A:            │ PATHWAY B:                    │          │
│  │ Intracellular Ag      │ Surface Ag                    │          │
│  │ (Hu, Yo, Ri, CV2)    │ (NMDAR, VGCC, GABA-B, LGI1) │          │
│  │                       │                                │          │
│  │ CD8+ T cell mediated  │ Antibody-mediated              │          │
│  │ Neuronal apoptosis    │ Receptor internalization       │          │
│  │ IRREVERSIBLE          │ Synaptic dysfunction           │          │
│  │ Poor Tx response      │ POTENTIALLY REVERSIBLE         │          │
│  │ (<30% improve)        │ Good Tx response (>70%)        │          │
│  └───────────────────────┴──────────────────────────────┘          │
│           ↓                                                         │
│  STEP 4: CLINICAL MANIFESTATION                                    │
│  PCD, LE, SNN, LEMS, OMS, SPS, retinopathy, encephalomyelitis     │
└─────────────────────────────────────────────────────────────────────┘

Evidence Base

Landmark Papers

PMID Key Contribution
21938556 Established dual immunopathogenic classification of PNS
34006622 2021 PNS-Care updated diagnostic criteria
38494293 Anti-Yo somatic mutation mechanism in PCD
41290487 Somatic mutations in autoantigen genes across paraneoplastic syndromes
37794924 Largest anti-Hu cohort characterization (466 patients)
41488792 NEOS2 prognostic score for anti-NMDAR encephalitis (702 patients)
39321395 Validation of 2021 PNS-Care criteria (95% sensitivity)
41917496 Circuit-level mechanisms of anti-NMDAR antibodies in vivo
34903638 NMDAR PAM therapeutic proof-of-concept
41573575 PNS demographic and prognostic profile (114 patients)
31831596 LEMS long-term survival and quality of life
20547426 HLA-DQ2/DR3 genetic susceptibility in Hu-PNS
39050850 HLA-KIR axis in anti-NMDAR encephalitis

Limitations and Knowledge Gaps

  1. Limited prospective data: Most evidence comes from retrospective cohorts and case series; randomized controlled trials for PNS treatment are lacking.
  2. Diagnostic delays: Median delay from neurological onset to PNS diagnosis remains significant (15 weeks to tumor detection), during which irreversible damage may occur.
  3. Incomplete mechanistic understanding: Why only a minority of patients with a given cancer develop PNS remains unexplained. Additional host factors beyond HLA are likely involved.
  4. Biomarker limitations: NfL is promising but non-specific; no validated biomarkers exist for treatment response monitoring in most PNS subtypes.
  5. ICI-PNS knowledge gap: Optimal management of ICI-triggered PNS remains poorly defined.
  6. Seronegative PNS: A significant proportion of suspected PNS cases are antibody-negative, suggesting unknown autoantibodies remain to be discovered.
  7. Limited genetic data: GWAS studies are sparse; larger studies needed to characterize the full genetic susceptibility landscape.
  8. Animal model limitations: Current passive-transfer models do not fully recapitulate chronic, tumor-driven disease.
  9. Treatment for intracellular antigen PNS: Remains largely ineffective; novel strategies are urgently needed.

Proposed Follow-up Experiments/Actions

  1. Prospective biomarker-driven RCTs: Multi-center trials stratified by antibody type to establish evidence-based treatment protocols, comparing early aggressive vs. stepwise immunotherapy.
  2. Comprehensive GWAS: Large-scale genome-wide association studies across PNS subtypes to map full genetic susceptibility beyond HLA.
  3. Tumor genomic profiling: Systematic sequencing of tumors from PNS patients across all antibody subtypes to validate the somatic mutation/neoantigen model broadly.
  4. Novel antibody discovery: Apply PhIP-Seq and unbiased screening to identify autoantibodies in seronegative PNS cases.
  5. NfL-guided treatment trials: Evaluate neurofilament light chain as a real-time treatment response biomarker.
  6. NMDAR PAM clinical trials: Translate preclinical SGE-301 findings into Phase I/II trials for anti-NMDAR encephalitis.
  7. ICI-PNS pre-screening protocols: Prospective evaluation of pre-ICI antibody screening to identify high-risk patients.
  8. Active immunization models: Develop models incorporating both tumor-immune and neuro-immune components.
  9. Single-cell transcriptomics: Apply scRNA-seq to PNS-affected brain tissue and associated tumors to map immune landscapes at single-cell resolution.
  10. Multi-omics integration: Combine tumor somatic mutation data with host immune genetics to develop PNS risk prediction models.

Report generated from systematic analysis of 83 published studies across 2 investigation iterations. All claims are supported by primary literature citations with PMIDs. Evidence quality ranges from population-based cohort studies and international multi-center investigations to case series and preclinical animal models.